On this page
Quick Reference
Overview and Recommendations
Key Facts
- •Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea in US hospitals, with an incidence of 46.6 per 10,000 admissions. The causative organism is an obligate anaerobic, Gram-positive, spore-forming bacillus that produces two primary exotoxins, toxin A (TcdA) and toxin B (TcdB), and, in some strains, a binary toxin (CDT). Spores are resistant to heat, alcohol, and many disinfectants, enabling environmental persistence and transmission.
- •Hypervirulent strains, particularly ribotype 027 (NAP1/BI), carry the binary toxin gene locus and are associated with higher 30-day attributable mortality (pooled RR 1.96) and increased rates of ICU admission, , or CDI-associated death (RR 1.88). The emergence of these strains has shifted the epidemiology of CDI, with community-associated cases now accounting for a growing proportion.
- •Pathogenesis hinges on disruption of the gut microbiome by antibiotics, which reduces colonization resistance and allows germination of ingested spores into toxin-producing vegetative cells. The toxins inactivate small GTPases (Rho, Rac, Cdc42), leading to actin cytoskeleton disorganization, tight junction disruption, epithelial apoptosis, and neutrophilic inflammation, the clinical hallmarks of diarrhea and colitis.
- •Stool (IL-1β), an inflammasome pathway cytokine, accurately differentiates CDI from asymptomatic carriage (AUROC 0.88) and from non-CDI diarrhea (AUROC 0.83), reflecting the degree of toxin-driven inflammation. This emerging biomarker may help address the critical gap between colonization and infection.
- •Recurrent CDI occurs in 15-30% of patients after initial therapy, driven by persistent dysbiosis and failure to restore secondary bile acid metabolism. Risk factors include age ≥65 years, continued non-CDI antibiotic use, severe underlying illness, and prior CDI episodes.
- •Antibiotic exposure is the dominant modifiable risk factor: each day of outpatient antibiotic therapy prior to admission increases the odds of subsequent CDI by 12.8%. Carbapenems and third-/fourth-generation cephalosporins carry the strongest association with healthcare facility-associated CDI, while clindamycin confers the highest risk for community-associated CDI (aOR 8.81 vs ).
Clinical Importance
- •Suspect CDI in any patient with ≥3 unformed stools in 24 hours for at least 1-2 days, especially if there is a history of antibiotic use within the past 8 weeks, hospitalization, or residence in a long-term care facility.
- •Ask about recent antibiotic exposure (type, duration, route), prior CDI episodes, PPI use, hospitalization history, and underlying conditions such as (IBD), malignancy, or immunosuppression.
- •Examine for abdominal tenderness, distension, decreased bowel sounds (suggesting ileus), fever, tachycardia, and signs of hypovolemia or shock. In severe cases, look for rigidity or guarding suggesting perforation.
- •Order diagnostic testing only on liquid stool (taking the shape of the container). Formed stools should be rejected. Use a multistep algorithm: first test for C. difficile antigen (GDH EIA) or use NAAT as initial screen; if positive, confirm with toxin A/B EIA. The diagnosis requires clinically significant diarrhea AND a positive toxin assay.
- •NAAT alone is not sufficient for diagnosis because it detects toxigenic C. difficile in colonized patients who have diarrhea from another cause. In a multicenter prevalence study, PCR used alone increased reported rates by up to 80% compared with a two-stage EIA-based algorithm.
- •Diagnostic criteria: diarrhea (≥3 unformed stools per day) plus a positive toxin test (EIA or CCNA) or a positive NAAT with a positive toxin EIA. NAAT-positive/toxin-negative results in diarrheal patients should prompt consideration of alternative causes; these patients may be colonized with another explanation for diarrhea.
- •Also consider alternative diagnoses: IBD flare, other infectious causes (norovirus, , enteropathogenic E. coli), laxative use, tube feeding, narcotic bowel syndrome, and ischemic colitis. In IBD patients, CDI cannot be distinguished from flare on clinical grounds alone; toxin-based multistep testing is essential.
- •Assess severity using IDSA criteria: non-severe (diarrhea only, no leukocytosis, normal creatinine), severe (WBC ≥15,000 cells/µL or serum creatinine >1.5 mg/dL), and fulminant (hypotension, ileus, toxic megacolon, or shock). Fulminant CDI carries a 30-40% mortality rate.
- •Risk stratify for recurrence: age ≥65 years, severe underlying illness, continued need for non-CDI antibiotics, prior CDI episode, and detection of binary toxin (cdtB) are associated with higher recurrence risk. The combination of eosinopenia and binary toxin positivity independently predicts inpatient mortality (OR 7.8).
- •In special populations, adjust approach: in transplant recipients, CDI occurs in 15% of SOT and 20% of HSCT recipients, with highest rates in the first 30 days. In pediatric patients, community-associated CDI is three times more common than healthcare-associated; fecal calprotectin >500 µg/g may help distinguish infection from carriage.
- •Consider diagnostic stewardship: clinical decision support alerts reduce inappropriate testing by 45-55% and CDI rates by 30-50%. Near-patient testing (point-of-care NAAT) reduces isolation time and length of stay without compromising accuracy.
- •Obtain baseline labs: CBC with differential, serum creatinine, electrolytes, and albumin. In patients with suspected fulminant CDI, check lactate, consider abdominal imaging (CT or plain film) to assess for megacolon or perforation.
Diagnosis and Treatment
- •For an initial episode of non-severe or severe CDI, initiate 200 mg orally twice daily for 10 days as the preferred first-line agent. Fidaxomicin reduces recurrence by approximately half compared with vancomycin and preserves the gut microbiome.
- •If fidaxomicin is unavailable or cost-prohibitive, use 125 mg orally four times daily for 10 days as an alternative. Vancomycin is effective but associated with higher recurrence rates (~20%) and greater dysbiosis.
- •Do not use as first-line therapy for initial CDI; it is inferior to vancomycin and fidaxomicin with higher recurrence rates.
- •For fulminant CDI (hypotension, ileus, toxic megacolon), initiate vancomycin 500 mg orally or by nasogastric tube four times daily plus intravenous metronidazole 500 mg every 8 hours. If ileus is present, add vancomycin 500 mg in 100 mL normal saline per rectum every 6 hours as a retention enema.
- •For first recurrence, if vancomycin was used initially, switch to fidaxomicin 200 mg BID for 10 days or use a vancomycin taper/pulse regimen (e.g., 125 mg QID for 10 days, then taper).
- •For patients with multiple recurrences or high risk of recurrence (age ≥65, immunocompromised, severe CDI, ongoing non-CDI antibiotics), add 10 mg/kg IV single dose during the CDI antibiotic course. Bezlotoxumab reduces recurrence from 28% to 17% (NNT=9).
- •Discontinue the inciting antibiotic(s) whenever possible. If ongoing antimicrobial therapy is required, switch to agents with lowest CDI risk: , , aminoglycosides, or narrow-spectrum β-lactams. Avoid carbapenems, third/fourth-generation cephalosporins, fluoroquinolones, and clindamycin.
- •Provide aggressive IV crystalloid resuscitation for dehydration. Monitor electrolytes, especially potassium and magnesium. Avoid antiperistaltic agents (opioids, loperamide) as they can precipitate toxic megacolon.
- •Discontinue proton pump inhibitors unless a clear indication exists. PPI use is associated with increased risk of CDI recurrence (OR 1.42 in IBD patients).
- •Do not routinely use for prevention or treatment of CDI. A large RCT in ICU patients found no reduction in CDI and a higher rate of probiotic-related infections.
- •Assess clinical response within 48-72 hours: resolution of diarrhea (≤3 unformed stools per day) and improvement in abdominal pain, fever, and leukocytosis. If no improvement, reassess severity, consider switching antibiotics (e.g., vancomycin to fidaxomicin), add IV metronidazole, or obtain surgical consultation.
- •For fulminant CDI with toxic megacolon, perforation, or refractory shock, obtain urgent surgical consultation. Subtotal with end ileostomy is the traditional approach; diverting loop ileostomy with colonic lavage is a less morbid alternative and should be considered in selected patients.
- •For recurrent CDI after multiple episodes (≥2), consider (FMT) or defined microbiota therapeutics such as SER-109 (VOWST) or RBX2660 (REBYOTA). FMT achieves 87.4% clinical resolution with consecutive treatments in immunocompromised patients.
- •Monitor for complications: VRE colonization, vitamin K deficiency (rare but can cause coagulopathy; treat with IV vitamin K 10 mg), and progression to severe disease. In elderly or malnourished patients with unexplained coagulopathy, suspect vitamin K deficiency.
- •For patients on concomitant non-CDI antibiotics, consider extending CDI therapy to cover the entire period of antibiotic use, although this is not guideline-recommended. Individualize based on clinical judgment.
- •In pediatric patients, vancomycin is first-line for initial CDI; fidaxomicin is reserved for recurrent disease. FMT is safe and effective for multiply recurrent cases in children.
- •In immunocompromised hosts (HCT, SOT, cancer), avoid metronidazole monotherapy; use fidaxomicin or vancomycin. FMT is safe and effective for recurrent CDI and should not be withheld due to immunosuppression alone.
Board Review — High Yield
- •Toxin B, Sufficient to cause human disease; endogenous anti-TcdB antibodies correlate with protection from recurrence (22% vs 35%).
- •Binary toxin (CDT), Associated with hypervirulent strains (ribotype 027); independently predicts worse outcomes and higher mortality, especially when combined with eosinopenia (OR 7.8).
- •Fidaxomicin, Preferred over vancomycin for initial CDI; reduces recurrence from ~17% to ~8% and spares the microbiome.
- •Bezlotoxumab, Monoclonal antibody against toxin B; reduces recurrence by ~10% when added to standard antibiotics (NNT=9).
- •Multistep diagnostic algorithm, GDH + toxin EIA preferred over NAAT alone; NAAT-positive/toxin-negative suggests colonization, not infection.
- •Vancomycin taper, 4-week pulse-and-taper regimen superior to 2-week pulse for preventing recurrence (adjusted RR 0.43).
- •Fecal microbiota transplantation (FMT), 87.4% resolution with consecutive treatments in recurrent CDI; safe in immunocompromised hosts.
- •Metronidazole, No longer first-line due to inferior efficacy; reserved for fulminant disease as IV adjunct.
- •Antibiotic spectrum index, Each unit increase per day of therapy increases CDI risk 1.09-fold; reducing antibiotic intensity is a key stewardship target.
- •Ribotype 027 (NAP1/BI), Produces binary toxin, has higher fluoroquinolone resistance, and is associated with increased 30-day attributable mortality (RR 1.96).
Deep Dive — Evidence Details
Definition, Classification and Causative Organisms
- ▸CDI is classified by acquisition (HA vs CA), episode number (initial vs recurrent), and severity (non-severe, severe, fulminant).
- ▸Recurrent CDI occurs in 15-30% of patients after initial treatment, driven by persistent dysbiosis and spore germination.
- ▸The pathogen is an anaerobic spore-former producing toxins A, B, and binary toxin, with hypervirulent ribotypes (e.g., RT027) causing more severe disease.
Clostridioides difficile infection (CDI) is a toxin-mediated diarrheal illness caused by the spore-forming, anaerobic bacterium Clostridioides difficile (formerly Clostridium difficile), ranging from mild self-limited diarrhea to life-threatening pseudomembranous colitis [9]D5[17]D5.
Also Called / Synonyms
- C. diff infection
- Clostridioides difficile infection (CDI)
- Clostridium difficile infection (historical)
- CDAD (C. difficile-associated disease)
- Clostridioides difficile colitis
Key Definitions Used in This Article
- Initial CDI: First episode of symptomatic infection.
- Recurrent CDI (rCDI): A second or subsequent episode occurring within 8 weeks of symptom resolution after treatment of a prior episode; 15-30% of patients experience recurrence after initial therapy [3]A1b[6]A1b.
- Healthcare-associated CDI (HA-CDI): Onset after ≥48 hours of hospitalization or within 4 weeks of discharge and no evidence of community acquisition [9]D5[53]B2c.
- Community-associated CDI (CA-CDI): Onset in the community with no inpatient stay in the prior 12 weeks and no known healthcare exposure [9]D5[53]B2c.
- Severe CDI: Defined by leukocytosis (white blood cell count ≥15 × 10⁹/L) or an elevated serum creatinine (≥1.5 mg/dL, using the 2017 IDSA/SHEA absolute threshold) [49]B2b.
- Fulminant CDI (FCDI): Characterized by hypotension (systolic BP ≤90 mm Hg or mean arterial pressure ≤65 mm Hg), ileus, megacolon, or shock; associated with a 30-40% mortality rate [48]B2b.
Classification Axes
CDI is classified along three axes that guide clinical decision-making:
| Classification | Categories | Key Distinguishing Feature |
|---|---|---|
| Acquisition | Healthcare-associated (HA) vs Community-associated (CA) | Timing of symptom onset relative to healthcare exposure [9]D5[53]B2c |
| Episode | Initial vs Recurrent (rCDI) | Number of prior episodes within 6 months [3]A1b[6]A1b |
| Severity | Non-severe, Severe, Fulminant | Objective markers of inflammation, renal function, end-organ dysfunction [48]B2b[49]B2b |
Clinical Significance
CDI is the leading cause of healthcare-associated infection in US hospitals, with an incidence of 46.6 per 10 000 admissions in a large multicenter cohort [30]B2b. It is a major driver of antibiotic-associated diarrhea and carries substantial morbidity, mortality, and healthcare costs. The has shifted: community-associated cases now account for a growing proportion, and hypervirulent strains (e.g., ribotype 027) have emerged [19]D5[53]B2c.
Causative Organism
Clostridioides difficile is an obligate anaerobic, Gram-positive, spore-forming bacillus that produces two primary exotoxins, toxin A (TcdA) and toxin B (TcdB), and, in some strains, a binary toxin (CDT) [19]D5[44]D5. The organism's spores are resistant to heat, alcohol, and many disinfectants, enabling environmental persistence and transmission [9]D5. Understanding the organism's microbiologic features and virulence factors is essential for appreciating its pathogenesis, which is explored in the next section.
Pearl: The pathogen is an anaerobic spore-former producing toxins A, B, and binary toxin, with hypervirulent ribotypes (e.g., RT027) causing more severe disease.
Microbiology and Pathogenesis
- ▸C. difficile pathogenesis requires microbiome disruption, spore germination, and toxin-mediated colonic injury; colonization resistance depends on microbiota-derived secondary bile acids.
- ▸Toxin B is the primary virulence determinant; endogenous anti-toxin B antibodies protect against recurrence, while binary toxin (CDT) independently worsens mortality, especially with concomitant eosinopenia.
- ▸Antimicrobial resistance, particularly reduced fidaxomicin susceptibility mediated by rpoB/rpoC mutations, can emerge during therapy and may transmit nosocomially, though often with fitness costs.
The pathogenesis of Clostridioides difficile infection hinges on three sequential events: disruption of the gut microbiome, germination of ingested spores into toxin-producing vegetative cells, and toxin-mediated inflammatory injury to the colonic epithelium. Each step is targetable, and the clinical spectrum, from asymptomatic colonization to pseudomembranous colitis, reflects where this cascade is interrupted.
Spore Formation and Colonization Resistance
C. difficile exists in two forms: a metabolically dormant spore and a toxin-producing vegetative cell [9]D5. Spores survive gastric acid, bile salts, and desiccation, and are the primary infectious unit. In a healthy gut, colonization resistance, conferred largely by the microbiota's conversion of primary bile acids (cholate, chenodeoxycholate) into secondary bile acids (deoxycholate, lithocholate), prevents spore germination and outgrowth [110]D5. Antibiotic exposure disrupts this ecosystem. The resulting dysbiosis reduces secondary bile acid concentrations, depletes short-chain fatty acid producers such as Bifidobacterium and Bacteroides, and creates a niche permissive for C. difficile spore germination [10]D5[81]D5. Notably, certain also directly impair mucosal barrier function independent of microbiome disruption, clindamycin and , but not tigecycline, compromise tight junctions and sensitize colonic epithelial cells to toxin activity [32]D5.
Toxin-Mediated Epithelial Injury
Once germinated, toxigenic C. difficile elaborates two large clostridial toxins: toxin A (TcdA, 308 kDa) and toxin B (TcdB, 270 kDa). Both are glucosyltransferases that inactivate small GTPases (Rho, Rac, Cdc42), leading to actin cytoskeleton disorganization, tight junction disruption, epithelial apoptosis, and a neutrophilic inflammatory cascade that produces the clinical hallmarks of diarrhea and colitis [109]D5. TcdB alone is sufficient to cause human disease, endogenous antibodies against TcdB, but not TcdA, correlate with protection from recurrence (22% recurrence with high anti-TcdB titers vs 35% with low/medium titers) [63]B2b. In about 5-7% of clinical isolates, a toxin A-predominant (A>>B) phenotype exists; these strains cause lethal murine CDI and are identified across multiple geographic centers [74]C4.
Stool interleukin-1β (IL-1β), an inflammasome pathway cytokine, accurately differentiates CDI from asymptomatic carriage (area under receiver operating curve [AUROC] 0.88) and from non-CDI diarrhea (AUROC 0.83), reflecting the degree of toxin-driven inflammation [75]B3b. Fecal calprotectin alone does not distinguish these groups.
Binary Toxin: An Additional Virulence Axis
Hypervirulent strains (e.g., ribotype 027, 078) carry the cdtA/cdtB gene locus, encoding binary toxin (CDT). CDT is an ADP-ribosyltransferase that disrupts the actin cytoskeleton, forming microtubule-based protrusions that enhance bacterial adherence [98]D5. CDT expression is independently associated with worse clinical outcomes: in a retrospective study of 215 CDI patients, those with fecal CdtB detected had higher 90-day mortality and more severe disease [99]B3b. The combination of CDT positivity plus peripheral eosinopenia (0 eosinophils/µL) synergistically increased inpatient mortality (OR 7.8) in one multicenter cohort, replicated in a separate national veterans' cohort (OR 6.1; 95% CI 1.5-23.9) [100]B3b. Ribotyping reveals strain diversity; the NAP1/BI/027 strain, characterized by binary toxin genes, a partial tcdC deletion that upregulates toxin production, and fluoroquinolone resistance, is associated with higher 30-day attributable mortality (pooled RR 1.96) and increased rates of intensive care admission, , or CDI-associated death (RR 1.88) [78]B2a.
Emerging Resistance and Fitness Trade-offs
Although and fidaxomicin resistance remains rare, reduced fidaxomicin susceptibility (MIC ≥ 2 µg/mL) has been reported and is associated with mutations in rpoB (encoding RNA polymerase) and rpoC, often incurring fitness costs, reduced toxin production, sporulation, and growth [73]B2b[77]C4[87]C4[40]D5. In a 3-year cohort, 5.6% of fidaxomicin-treated patients harbored isolates with MICs 8-32 µg/mL, including clonally related strains suggesting nosocomial transmission [73]B2b. Importantly, binary toxin-positive strains (including ribotype 027) more frequently exhibit decreased susceptibility to vancomycin, , and other agents compared with binary toxin-negative strains [86]C4. These trends underscore the need for ongoing surveillance, particularly as antibiotic stewardship reduces selective pressure in healthcare settings [92]C4[93]C4.
Pearl: In patients with CDI, a low clinical pretest probability for infection combined with a positive NAAT but negative toxin immunoassay should raise suspicion for colonization rather than true infection; IL-1β stool levels >50 pg/mL may help confirm active inflammatory disease and guide treatment decisions [75]B3b.
| Virulence Factor | Mechanism | Clinical Correlate |
|---|---|---|
| Toxin A (TcdA) | Glucosyltransferase → inactivates Rho GTPases → cytoskeletal disruption, apoptosis | Colitis, diarrhea; A>>B strains cause disease in ~5-7% of CDI |
| Toxin B (TcdB) | Same mechanism as TcdA; sufficient alone for human disease | Recurrence risk inversely correlates with anti-TcdB antibody titers |
| Binary toxin (CDT) | ADP-ribosyltransferase → actin disruption, microtubule protrusions | Higher 90-day mortality; eosinopenia+CDT synergy (OR 7.8 for inpatient mortality) |
| Spores | Dormant form; survive gastric acid, germinate in bile acid-rich milieu | Infectious unit; recurrence driven by spore persistence |
Epidemiology, Transmission and Risk Factors
- ▸CDI incidence in the US declined 24% from 2011-2017 driven by reductions in healthcare-associated cases, while community-associated rates remained stable [130].
- ▸Antibiotic exposure, particularly carbapenems, cephalosporins, and clindamycin, is the dominant modifiable risk factor; concurrent PPI use synergistically increases risk [114,142].
- ▸Asymptomatic carriers and recently hospitalized household members are important sources of community transmission [9,155].
The spore-forming nature of C. difficile ensures its persistence in healthcare environments and the community, producing an epidemiologic profile dominated by antibiotic-driven risk and a shifting balance between healthcare-associated (HA) and community-associated (CA) cases.
Incidence and Temporal Trends
In the United States, the estimated national burden of CDI was 462,100 cases (95% -495,600) in 2017 [130]B2c. After adjusting for nucleic acid amplification test use, the total burden decreased by 24% (95% CI 6%-36%) from 2011 to 2017, driven by a 36% decline in HA-CDI; CA-CDI rates remained unchanged [130]B2c. Point-prevalence surveys confirm that
C. difficile is the most common healthcare-associated infection, with overall HAI prevalence falling from 4.0% to 3.2% between 2011 and 2015, partly due to reductions in surgical-site and urinary tract infections [131]B2c. Similar trends are observed elsewhere: adult HA-CDI in Canada fell 19.9% from 2015 to 2022, while CA-CDI rates held steady [53]B2c. Sweden reported a 22% decrease in CDI incidence from 2012 to 2016 [54]B2c, while Hong Kong saw a plateau after years of increase [154]B2c. During the pandemic, CDI incidence declined significantly (pooled incidence rate ratio 0.80, 95% CI 0.67-0.97), likely reflecting enhanced hand hygiene, environmental cleaning, and [126]A1a.
Demographic and Geographic Distribution
Incidence rises sharply with age; adults ≥65 years account for the majority of cases [130]B2c. The male-to-female ratio is roughly equal, though sex hormones may modulate immune response and microbiome composition, influencing susceptibility [20]D5. Carrier prevalence among acutely admitted emergency department patients is 1.8%, associated with advanced age and comorbidity [128]B3b. In the U.S., CDI incidence is higher in the Northeast and among white populations, though racial disparities may reflect differences in healthcare exposure rather than biologic risk [130]B2c.
Transmission
C. difficile spores persist for months on environmental surfaces and are resistant to alcohol-based hand sanitizers. Asymptomatic carriers, patients colonized without diarrhea, are a major reservoir for transmission in both hospitals and the community [9]D5. Household exposure is a significant vector: insurance claims data show that CDI incidence is 73% higher among persons with a family member hospitalized in the prior 60 days, with a dose-response relationship to length of hospitalization [155]B3b. Community reservoirs also include food animals, and ribotype 078 strains are shared between pigs and humans, indicating zoonotic transmission [152]C4.
Risk Factors
Antibiotic exposure is the dominant modifiable risk factor. Each day of outpatient antibiotic therapy prior to admission increases the odds of subsequent CDI by 12.8% (95% CI 12.2%-13.4%) [30]B2b. Carbapenems and third-/fourth-generation cephalosporins carry the strongest association with healthcare facility-associated CDI [114]A1a. For community-associated CDI, clindamycin confers the highest risk (adjusted odds ratio [aOR] 8.81 vs ) [137]B2b. Concurrent proton pump inhibitor (PPI) use amplifies antibiotic-associated risk: the combined effect of recent PPI and antibiotic exposure yields an odds ratio of **17.51 ** [142]B3b.
| Risk Factor | Odds Ratio / Relative Risk (95% CI) | Evidence Source |
|---|---|---|
| Any antibiotic exposure (vs none) | RR 2.79 (2.27-3.43) for HAD; aRR 5.31 (2.23-12.69) for CDI | [76]B3b |
| Clindamycin (CA-CDI, vs doxycycline) | aOR 8.81 (7.76-10.00) | [137]B2b |
| Third-/fourth-generation cephalosporins (HCFA-CDI) | OR >2.0 (pooled) | [114]A1a |
| Carbapenems (HCFA-CDI) | OR >2.0 (pooled) | [114]A1a |
| Recent PPI use (alone) | OR 2.65 (2.54-2.76) | [142]B3b |
| Combined PPI + any antibiotic | OR 17.51 (17.48-17.53) | [142]B3b |
| Age (per year increase) | MD 2.56 years (0.75-4.36) | [124]A1a |
| Inflammatory bowel disease | OR 1.69 (1.31-2.21) for recurrence | [124]A1a |
| Malignancy | OR 1.51 (1.11-2.07) for recurrence | [133]B2b |
| Household hospitalization exposure | IRR 1.73 (1.56-1.92) | [155]B3b |
| Enteral nutrition (ICU) | OR 2.11 (1.37-3.24) for CDAD | [127]A1a |
| Mechanical ventilation (ICU) | OR 1.61 (1.12-2.33) for CDAD | [127]A1a |
| Kidney disease (ICU) | OR 1.74 (1.04-2.90) for CDAD | [127]A1a |
Special Populations
Transplant recipients carry a disproportionately high burden: CDI occurs in 15% of solid organ and 20% of hematopoietic stem cell transplant recipients, with highest rates in the first 30 days post-transplant (adjusted incidence rate ratio 6.64 for SOT, 2.85 for HSCT) [144]B2b. Patients with hematologic malignancies, particularly acute leukemia, have a pooled CDI incidence of 8.33% (95% CI 6.24%-), with all-cause mortality of 20.49% [123]A1a. In inflammatory bowel disease, CDI is a common trigger of flares and is associated with higher rates [15]A1c. Pediatric CDI incidence has declined in Canada by 29.6% for HA-CDI and 58.3% for CA-CDI from 2015-2022 [53]B2c; recurrence occurs in approximately 31% of pediatric patients, associated with reduced fecal short-chain fatty acid-producing bacteria [147]B2b.
Pearl: Asymptomatic carriers and recently hospitalized household members are important sources of community transmission [9]D5[155]B3b.
Clinical Presentation
- ▸CDI presents along a spectrum from watery diarrhea to fulminant colitis; the cardinal symptom is ≥3 unformed stools per day with abdominal pain.
- ▸Toxin-positive CDI is associated with more severe clinical presentation (higher age, greater stool frequency, higher WBC) and carries a higher recurrence risk (aOR 1.89) compared with NAAT-positive-only infection [163].
- ▸In patients with IBD, CDI cannot be distinguished from IBD flare on clinical grounds alone; toxin-based multistep testing is essential [8,15].
Once ingested C. difficile spores germinate in a disrupted gut microbiome, the clinical spectrum ranges from asymptomatic colonization to fulminant colitis. The incubation period is typically days to weeks after antibiotic exposure, but symptoms can begin as late as 8 weeks after the inciting agent.
Presenting Symptoms
The cardinal symptom is diarrhea: ≥3 unformed stools in 24 hours for at least 1-2 days [163]B3b. Patients also report cramping abdominal pain, bloating, and nausea. Fever (temperature >38.0°C) occurs in up to half of cases. The diarrhea is watery and non-bloody in most cases; gross blood suggests alternative or concomitant pathology (e.g., , ischemic colitis). Stool concentrations of the inflammasome cytokine interleukin-1β (IL-1β) discriminate CDI from non-CDI diarrhea with an area under the receiver-operating characteristic curve (AUC) of 0.83 [75]B3b.
Physical Examination and Clinical Staging
Abdominal examination may reveal diffuse tenderness with guarding, diminished bowel sounds with ileus, or distension from . Systemic signs, tachycardia, hypotension, fever, indicate progression to fulminant colitis. The IDSA classifies severity as: mild/moderate (diarrhea only); severe (white blood cell count ≥15,000 cells/µL or serum creatinine >1.5 mg/dL); and fulminant (hypotension, ileus, or megacolon) [120]B2b. Toxin-positive disease (detected by ) correlates with greater severity: toxin-positive patients are more often aged ≥65 years (48.2% vs 38.0%), have ≥3 unformed stools for ≥1 day (43.9% vs 36.6%), and have WBC ≥15,000 (31.4% vs 21.4%) compared with NAAT-positive-only cases [163]B3b.
| Severity | Defining Criteria |
|---|---|
| Mild/Moderate | Diarrhea (≥3 unformed stools/day), no leukocytosis, normal creatinine |
| Severe | WBC ≥15,000 cells/µL or serum creatinine >1.5 mg/dL |
| Fulminant | Hypotension, ileus, toxic megacolon, or required |
| Adapted from IDSA guideline definitions [120]B2b. |
Atypical Presentations
In patients with , CDI mimics an IBD flare, increased stool frequency, urgency, hematochezia, making clinical distinction unreliable without diagnostic testing [8]D5. The recommends toxin-based multistep assays for these patients [15]A1c. In children, C. difficile is detected in 4.4% of hospitalized children aged ≥2 years with acute gastroenteritis but also in 2.4% of healthy controls, so clinical correlation is essential [174]B3b. In elderly, frail, or malnourished patients, CDI can precipitate severe vitamin K deficiency leading to coagulopathy and spontaneous hematomas; this rare complication responds rapidly to parenteral vitamin K [171]C4.
Red Flags
Progression from mild to severe disease can occur within 24-48 hours. Immediately actionable findings include: WBC >35,000 cells/µL, lactate >5.0 mmol/L, hemodynamic instability, abdominal rigidity or distension, and decreased bowel sounds (impending ileus). These features should prompt urgent surgical consultation.
Pearl: In patients with IBD, CDI cannot be distinguished from IBD flare on clinical grounds alone; toxin-based multistep testing is essential [8]D5[15]A1c.
Diagnosis and Workup
- ▸A multistep algorithm (GDH EIA + toxin EIA) is recommended over NAAT alone to distinguish CDI from asymptomatic carriage.
- ▸Cycle threshold values from PCR platforms correlate with CDI probability but are not yet widely used for clinical decision-making.
- ▸Stool IL-1β and host serum markers (IL-6, GCSF, anti-toxin IgG) are emerging biomarkers that accurately differentiate CDI from colonization and non-CDI diarrhea.
Given the nonspecific nature of diarrheal illness in hospitalized patients, laboratory confirmation is mandatory before attributing symptoms to CDI. A multistep diagnostic algorithm, not nucleic acid amplification testing (NAAT) alone, is the recommended approach because NAAT cannot distinguish colonization from toxin-mediated disease [178]B2b.
Gold-Standard Test and Reference Methods
Toxigenic culture (TC) is the most commonly used reference standard for CDI diagnosis [168]A1a. Cell cytotoxicity neutralization assay (CCNA) is an alternative gold standard that detects functional toxin B. Both are impractical for routine clinical use due to turnaround times of 48-96 hours, but they remain the benchmarks against which all rapid assays are validated.
Laboratory Studies
Diagnostic assays fall into three categories:
| Test | Target | Sensitivity | Specificity | Turnaround |
|---|---|---|---|---|
| NAAT (PCR, LAMP) | Toxin A/B genes (tcdA, tcdB) | >90% | 60-80% | 1-4 hours |
| GDH EIA | Glutamate dehydrogenase (common antigen) | 91.6% (89.1-94.0%) [168]A1a | Moderate; requires toxin confirmation | 1-2 hours |
| Toxin A/B EIA | Toxins A and/or B | 40-80% | >95% | 1-2 hours |
NAAT alone is not sufficient for diagnosis because it detects toxigenic C. difficile in colonized patients who have diarrhea from another cause. In a multicenter prevalence study, PCR used alone increased reported rates by up to 80% compared with a two-stage EIA-based algorithm [106]C4. The false-positive rate translates into unnecessary treatment, isolation, and cost.
Cycle threshold (Ct) values provide semiquantitative information. NAAT platforms have platform-specific Ct zones that correlate with CDI probability (e.g., GeneXpert Ct ≤24.00 → >90% probability; Ct ≥33.61 → <10% probability) [160]C4. In practice, very low Ct values (≤24-27) suggest true infection, while high values (≥33-37) suggest colonization, but Ct is not yet widely used for clinical decision-making.
Toxin EIA remains the most specific rapid test: a positive toxin result strongly supports true CDI. However, its modest sensitivity means a negative toxin result does not exclude disease, which is why it is used within a multistep algorithm rather than as a standalone test.
Diagnostic Algorithm
The Infectious Diseases Society of America (IDSA) recommends the following stepwise approach:
- Select the right specimen, only liquid stools (taking the shape of the container) should be tested. Formed stools should be rejected. Do not repeat testing within 7 days of a positive result.
- First stage, test for C. difficile antigen (GDH EIA) or use NAAT as the initial screen.
- Second stage, confirm with toxin A/B EIA (or CCNA) if GDH-positive or NAAT-positive. The diagnosis of CDI requires clinically significant diarrhea AND a positive toxin assay (or NAAT + toxin EIA). NAAT-positive/toxin-negative results in diarrheal patients should prompt consideration of alternative causes; these patients may be colonized with another explanation for diarrhea.
- Tiebreaker, if GDH-positive/toxin-negative and suspicion remains high, send for toxigenic culture (reference lab).
Diagnostic stewardship: Clinical decision support alerts built into the electronic health record reduce inappropriate testing by 45-55% and CDI rates by 30-50% [158]B2a. Near-patient testing (point-of-care NAAT) reduces isolation time by a mean 9.4 hours and shortens length of stay without compromising diagnostic accuracy [159]A1b.
Emerging Biomarkers
Stool interleukin (IL)-1β, an inflammasome-associated cytokine, can accurately differentiate CDI from asymptomatic carriage (ROC-AUC 0.88) and from non-CDI diarrhea (ROC-AUC 0.83) [75]B3b. A multipredictor model combining IL-1β and IgA anti-toxin A achieved an ROC-AUC of 0.93 [75]B3b. Host serum markers, particularly IL-6, granulocyte colony-stimulating factor, tumor necrosis factor-α, and IgG anti-toxin A, also separate CDI from colonized patients [162]B3b. These biomarkers are not yet commercially available but address the critical gap between colonization and infection.
Differential Diagnosis
In hospitalized patients with diarrhea, alternative diagnoses include:
- Inflammatory bowel disease (IBD) flare, up to 20% of IBD patients harboring toxigenic C. difficile have colonization rather than infection [8]D5. A multistep toxin-based algorithm is essential in this population.
- Other infectious causes, norovirus, enteropathogenic Escherichia coli, Salmonella, and other enteric pathogens. In one series, coinfections were present in 31% of positive stool samples when multiplex PCR was used [199]C4.
- Laxative use, tube feeding, narcotic bowel syndrome, and ischemic colitis.
- Antibiotic-associated diarrhea without CDI, many cause diarrhea independent of C. difficile.
Controversies and Guideline Disagreement
The major diagnostic controversy is NAAT-only vs. multistep algorithm. The IDSA/SHEA guidelines recommend a multistep algorithm (GDH + toxin EIA) [158]B2a, while some centers use NAAT alone for speed. Data from the MODIFY I/II trials show that patients diagnosed by toxin EIA/CCA had a substantially larger bezlotoxumab treatment benefit (relative reduction in recurrence -) compared with those diagnosed by tgPCR alone (-29.1%) [178]B2b, reinforcing that toxin-based diagnosis identifies patients most likely to benefit from specific anti-CDI therapy. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) similarly endorses a two-step approach with toxin detection as the final arbiter.
Pearl: A multistep algorithm (GDH EIA + toxin EIA, or NAAT + toxin EIA) outperforms NAAT alone for diagnosing true CDI; a positive NAAT in diarrheal stool does not prove toxin-mediated disease and leads to overdiagnosis and overtreatment, the threshold for sending a toxin EIA after a positive NAAT should be zero.
| Test | Target | Sensitivity | Specificity | Turnaround |
|---|---|---|---|---|
| NAAT (PCR, LAMP) | Toxin A/B genes | >90% | 60-80% | 1-4 hours |
| GDH EIA | Glutamate dehydrogenase | 91.6% [168]A1a | Moderate | 1-2 hours |
| Toxin A/B EIA | Toxins A and/or B | 40-80% | >95% | 1-2 hours |
| Toxigenic culture (TC) | Toxigenic C. difficile | >95% | >95% | 48-96 hours |
| Cell cytotoxicity assay (CCNA) | Functional toxin B | >90% | >99% | 24-48 hours |
Severity Assessment and Risk Stratification
- ▸Binary toxin positivity (cdtB) is associated with severe CDI and reduced susceptibility to vancomycin and metronidazole, warranting consideration for escalated therapy.
- ▸Fecal calprotectin may serve as a supplementary marker for disease severity but is not reliable for diagnosis or prognosis.
- ▸Machine learning models like RecurCDI-IBD show promise for predicting recurrent CDI, with AUC 0.88 in IBD patients.
Once CDI is confirmed, severity assessment dictates the intensity of therapy and the need for hospital admission. Several validated tools and clinical markers guide this stratification, though their applicability varies across populations.
Established Severity Criteria
Standard definitions of severe CDI (e.g., leukocytosis >15 000 cells/μL or serum creatinine >1.5 mg/dL) are widely used but have not been uniformly validated in immunocompromised hosts. In a meta-analysis of non-transplanted adults with hematologic malignancy, the pooled incidence of severe CDI was 14.49% and severe-complicated CDI 4.60% [123]A1a. These data highlight the need for tailored thresholds in populations with blunted inflammatory responses.
Predictors of Severe Disease and Healthcare-Facility-Onset CDI
A systematic review of 12 diagnostic models for healthcare-facility-onset CDI identified the most frequent predictors: advanced age, receipt of high-risk , history of hospitalization, and history of CDI [200]B2a. However, only 2 models underwent external validation, and all had a high risk of bias, limiting their clinical implementation [200]B2a.
Fecal calprotectin has been investigated as a non‑invasive marker of intestinal inflammation. A systematic review concluded that calprotectin is not an ideal indicator for diagnosis or prognosis but may serve as a potential indicator for assessing disease severity, with higher levels observed in patients requiring treatment or those with detectable toxins [204]B2a.
Binary Toxin and Antimicrobial Susceptibility
Detection of the binary toxin gene (cdtB) is a strong marker of severe disease. In a single‑center study, cdtB‑positive isolates (mostly ribotype 027) were associated with higher MICs of , , tigecycline, clindamycin, and compared to cdtB‑negative strains [86]C4. All six isolates resistant to vancomycin and/or metronidazole were cdtB‑positive [86]C4. Patients with severe CDI were significantly more likely to be infected with cdtB‑positive strains, supporting the recommendation to test for binary toxin when severe disease is suspected [86]C4.
Risk Stratification for Recurrence
Predicting recurrent CDI (rCDI) is critical for high‑risk groups. In patients with inflammatory bowel disease (IBD), a machine‑learning model (RecurCDI‑IBD) using XGBoost achieved an area under the curve of 0.88 and accuracy 80.05% for predicting rCDI within 60 days [207]B2b. Key predictors included IBD subtype, sex, steroid use, anti‑TNF agents, and comorbidities such as chronic pulmonary and renal disease [207]B2b. Though developed in an IBD cohort, this model illustrates the potential of data‑driven risk stratification.
| Predictor or Marker | Association with Severity or Recurrence | Evidence Level |
|---|---|---|
| Advanced age, high‑risk antibiotics, prior hospitalization, prior CDI | Predictors of healthcare‑facility‑onset CDI | Systematic review (high risk of bias) [200]B2a |
| Binary toxin (cdtB) positivity | Associated with severe disease and higher MICs | Single‑center study [86]C4 |
| Fecal calprotectin | Potential severity marker, not diagnostic | Systematic review [204]B2a |
| IBD subtype, steroids, anti‑TNF, comorbidities | Predictors of recurrence in IBD (AUC 0.88) | Machine‑learning model [207]B2b |
These severity and risk assessments directly inform the choice of empiric therapy and the decision to escalate care, as detailed in the following section on empiric .
Pearl: Machine learning models like RecurCDI-IBD show promise for predicting recurrent CDI, with AUC 0.88 in IBD patients.
Empiric Management, Acute Care and Source Control
- ▸Fidaxomicin is the preferred first-line agent for initial non-severe and severe CDI (IDSA/SHEA 2021 strong recommendation); vancomycin is an acceptable alternative.
- ▸For fulminant CDI, high-dose oral vancomycin plus IV metronidazole is indicated, with early surgical consultation for source control.
- ▸Source control includes discontinuing inciting antibiotics and switching to low-risk agents; for fulminant cases, diverting loop ileostomy or colectomy may be life-saving.
- ▸Supportive care involves aggressive fluid resuscitation, avoidance of antiperistaltic agents and PPIs, and no role for probiotics.
Once severity is classified (non-severe, severe, or fulminant), empiric therapy must begin immediately while definitive microbiologic results are pending. The choice of agent, route, and adjunctive measures depends on disease severity, risk of recurrence, and the need for source control. This section outlines the initial antibiotic strategy, acute supportive care, and the critical role of source control, all of which precede the detailed dosing and de-escalation decisions covered in the next section.
Step 1: Confirm Severity and Determine Disposition
Severity classification (Section 6) drives both the antibiotic choice and the care setting. Patients with non-severe or severe CDI (WBC ≤15,000 cells/µL and creatinine ≤1.5× baseline) can be managed as outpatients or on a general medical ward if hospitalization is required for other reasons. Patients with fulminant CDI (hypotension, shock, ileus, megacolon) require ICU-level care and immediate surgical consultation [1]A1c (1c).
Step 2: Empiric Antibiotic of Choice
The IDSA/SHEA 2021 focused update recommends fidaxomicin 200 mg orally twice daily for 10 days as the preferred first-line agent for an initial episode of non-severe and severe CDI (strong recommendation, moderate-quality evidence) [1]A1c (1c). Fidaxomicin is superior to in reducing recurrence (8.1% vs 17.3% in the ridinilazole phase 3 trial;) [4]A1b (1b) and preserves the gut microbiome better than vancomycin [4]A1b (1b). Vancomycin 125 mg orally four times daily for 10 days remains an acceptable alternative when fidaxomicin is unavailable or cost-prohibitive [1]A1c (1c). should not be used for initial therapy because of inferior efficacy and higher recurrence rates [1]A1c (1c).
For fulminant CDI, the IDSA/SHEA guideline recommends vancomycin 500 mg orally or by nasogastric tube four times daily plus intravenous metronidazole 500 mg every 8 hours [1]A1c (1c). If ileus is present, vancomycin 500 mg in 100 mL normal saline per rectum every 6 hours can be added as a retention enema [1]A1c (1c). ESCMID has also endorsed fidaxomicin and tigecycline as part of combination therapy for severe-complicated CDI, though this is not yet standard in North America [223]D5 (5).
For first recurrence, fidaxomicin is again preferred; if vancomycin was used initially, a switch to fidaxomicin or a vancomycin taper/pulse regimen is recommended [1]A1c (1c). For patients with multiple recurrences or high risk of recurrence (age ≥65 years, immunocompromised, severe CDI, ongoing non-CDI ), bezlotoxumab 10 mg/kg IV single dose should be added to standard antibiotic therapy [1]A1c (1c). Bezlotoxumab, a monoclonal antibody against toxin B, reduced recurrence from 28% to 17% in pooled phase 3 trials (NNT = 9) [1]A1c (1c).
Step 3: Source Control, A First-Class Decision
Source control in CDI means discontinuing the inciting antibiotic(s) whenever possible. If ongoing antimicrobial therapy is required for a concurrent infection, the clinician should switch to agents with the lowest CDI risk: , , aminoglycosides, or narrow-spectrum β-lactams [30]B2b (2b). Carbapenems, third/fourth-generation cephalosporins, fluoroquinolones, and clindamycin carry the highest risk and should be avoided [114]A1a (1a). Fidaxomicin may be preferable to vancomycin in patients who must continue concomitant antibiotics because of its narrower spectrum and lower impact on the microbiome [70]D5 (5).
For fulminant CDI with toxic megacolon, perforation, or refractory shock, surgical source control is life-saving. Subtotal with end ileostomy has been the traditional approach, but diverting loop ileostomy with colonic lavage (using vancomycin flushes) is a less morbid alternative that preserves the colon and has shown comparable mortality benefit in selected patients [1]A1c (1c). Early surgical consultation (within 24 hours of fulminant criteria) is recommended; delay increases mortality [1]A1c (1c).
Step 4: Supportive Care
- Fluid resuscitation: Aggressive intravenous crystalloids for dehydration; monitor for electrolyte disturbances (especially potassium and magnesium) [17]D5 (5).
- Avoid antiperistaltic agents: Opioids and loperamide can mask symptoms and precipitate toxic megacolon; they are contraindicated in active CDI [17]D5 (5).
- Discontinue acid suppression: Proton pump inhibitors (PPIs) are associated with increased risk of CDI recurrence (OR 1.42 in IBD patients) [227]B2b (2b). PPIs should be stopped unless a clear indication exists [70]D5 (5).
- : Not recommended. A large randomized trial of Lactobacillus rhamnosus GG in ICU patients found no reduction in CDI and a higher rate of probiotic-related infections (1.1% vs 0.1%) [211]A1b (1b).
Step 5: Monitoring and Escalation
Clinical response should be assessed within 48-72 hours. Resolution of diarrhea (≤3 unformed stools per day) and improvement in abdominal pain, fever, and leukocytosis indicate adequate response. If no improvement or worsening occurs, reassess severity, consider repeat imaging for megacolon, and escalate therapy: switch from vancomycin to fidaxomicin, add bezlotoxumab, or obtain surgical consultation [1]A1c (1c).
Once clinical stability is achieved, the focus shifts to completing the prescribed course and planning for recurrence prevention, topics covered in the next section on definitive therapy.
Figure 1: Empiric algorithm for CDI (adapted from IDSA/SHEA 2021 [1]A1c and AGA 2026 [212]D5).
| Drug | Indication / Line | Dose | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Vancomycin | Alternative first-line | 125 mg PO QID x10 d | Multiple RCTs | Clinical cure ~80%; recurrence ~20% | 1b |
| Vancomycin (high-dose) + IV metronidazole | Fulminant CDI | Vancomycin 500 mg PO/NG QID + metronidazole 500 mg IV q8h | IDSA guideline [1]A1c | Recommended for fulminant disease | 1c |
| Bezlotoxumab | Adjunct for high-risk recurrence | 10 mg/kg IV single dose | MODIFY I/II [1]A1c | Recurrence 17% vs 28% (placebo); NNT=9 | 1b |
| Fidaxomicin (recurrence) | First recurrence | 200 mg PO BID x10 d | IDSA guideline [1]A1c | Preferred over vancomycin for recurrence | 1c |
Pearl: For an initial CDI episode, start fidaxomicin 200 mg twice daily for 10 days, it halves recurrence risk compared with vancomycin and preserves the microbiome; for fulminant disease, escalate immediately to high-dose oral vancomycin plus IV metronidazole and obtain a surgical consult within 24 hours [1]A1c (1c).
Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
- ▸Fidaxomicin 200 mg twice daily for 10 days is the preferred first-line agent for initial CDI (IDSA/SHEA 2021, strong recommendation, high-quality evidence) due to lower recurrence rates versus vancomycin.
- ▸Vancomycin 125 mg four times daily for 10 days remains an acceptable alternative; metronidazole is not recommended for routine use.
- ▸Shortened treatment durations (5-7 days vancomycin, 5 days fidaxomicin) may be effective in patients with prompt clinical response, and de-escalation of concomitant non-CDI antibiotics is critical to reduce recurrence risk.
From empiric , the clinician now moves to definitive pathogen-directed therapy. The IDSA/SHEA 2021 focused update [1]A1c[2]A1c reshaped the treatment landscape by promoting fidaxomicin as the preferred first-line agent for an initial episode of CDI, regardless of severity (strong recommendation, high-quality evidence). remains an acceptable alternative but is no longer the default. is not recommended for initial treatment due to inferior efficacy and higher recurrence rates [1]A1c[2]A1c.
Step 1: Selecting Definitive Antibiotic Therapy
For a first episode of non-severe or severe CDI, the IDSA/SHEA 2021 guideline recommends fidaxomicin 200 mg orally twice daily for 10 days [1]A1c[2]A1c. This recommendation is driven by a consistent reduction in recurrent CDI (rCDI) compared with vancomycin. In the phase 3 Ri-CoDIFy trials, fidaxomicin reduced recurrence from 17.3% to 8.1% (risk difference -, 95% CI - to -4.5%) [4]A1b. Vancomycin 125 mg orally four times daily for 10 days is an acceptable alternative when fidaxomicin is unavailable or contraindicated [1]A1c[2]A1c. Metronidazole (500 mg IV three times daily) should be reserved for situations where oral therapy is absolutely impossible and other agents are not available, as it achieves low fecal concentrations and inferior clinical cure [1]A1c[2]A1c[223]D5.
Step 2: PK/PD and Route Considerations
Both fidaxomicin and vancomycin act luminally with minimal systemic absorption. Fidaxomicin has a narrow spectrum that spares key anaerobes, preserves microbiota diversity, and promotes recovery of secondary bile acid metabolism, mechanisms that drive its lower recurrence risk [4]A1b[70]D5. Vancomycin, by contrast, broadly suppresses gut anaerobes and can worsen dysbiosis, increasing the risk of rCDI [4]A1b. Oral administration is essential; if the patient cannot take oral medications, fidaxomicin and vancomycin can be given via nasogastric or nasojejunal tube. Intravenous therapy (metronidazole ± tigecycline) is reserved for severe-complicated CDI with ileus or toxic megacolon, where luminal delivery is compromised [1]A1c[223]D5.
Step 3: Duration and De-escalation
The standard duration for both fidaxomicin and vancomycin is 10 days. However, accumulating evidence supports shortened courses in patients with prompt clinical response. An observational study of 25 patients treated with vancomycin for 5-7 days or fidaxomicin for 5 days reported an rCDI rate of 8.0% versus 22.7% with standard 10-day therapy (P not significant), suggesting that abbreviated courses may be effective [38]B2b (2b). De-escalation of concomitant non-CDI is critical: each additional day of broad-spectrum therapy increases CDI risk [76]B3b, and minimizing the number, spectrum, and duration of concurrent antibiotics reduces recurrence [70]D5. A target trial emulation found that de-escalation of antibiotic therapy was associated with fewer CDI episodes (2.2% vs 3.8%) [240]B2b. When concomitant antibiotics are unavoidable, fidaxomicin may be preferred over vancomycin due to its lesser microbiome disruption [70]D5.
Step 4: Treatment Failure Protocol
Clinical failure is defined as persistent diarrhea (≥3 unformed bowel movements per day) beyond day 5-7 of appropriate therapy. In this setting, consider:
- Switch from vancomycin to fidaxomicin (or vice versa).
- Adding intravenous metronidazole (500 mg every 8 hours) if severe-complicated disease is present.
- Surgical consultation for if toxic megacolon or perforation develops. Emerging resistance is a concern: reduced fidaxomicin susceptibility (MIC ≥2 µg/mL) was detected in 5.6% of treated patients in one cohort, with on-therapy emergence documented [73]B2b. Similarly, vancomycin-nonsusceptible C. difficile has been reported in up to 26% of clinical isolates in one study [176]B2b. Routine susceptibility testing is not standard but should be considered in recurrent or refractory cases [119]C4.
Step 5: Prevention of Recurrence After Initial Therapy
For patients at high risk of rCDI (age ≥65 years, severe underlying illness, continued need for non-CDI antibiotics, prior CDI episode), the IDSA/SHEA 2021 guideline recommends adding bezlotoxumab 10 mg/kg single intravenous dose during the CDI antibiotic course [1]A1c[2]A1c (strong recommendation, moderate-quality evidence). Bezlotoxumab, a monoclonal antibody against toxin B, reduced rCDI from 28% to 16% in MODIFY trials (HR 0.62) [63]B2b. A recent precision-randomized trial (BEYOND) confirmed benefit in high-risk patients (72.7% vs 31.8% composite endpoint; P = 0.015) [248]B2b (2b). For patients with multiple recurrences, a vancomycin taper (125 mg twice daily for 7 days, then 125 mg once daily for 7 days) after a standard course reduced early recurrence at day 38 compared with a 2-week pulse alone (adjusted RR 0.43, 95% CrI 0.19-0.89; posterior probability 99.0%) [241]A1b (1b). is discussed in the Prevention and Infection Control section.
What NOT to Do
- Do not use metronidazole as first-line therapy for initial CDI; it is inferior to vancomycin and fidaxomicin [1]A1c[2]A1c.
- Do not routinely extend CDI treatment beyond 10 days in the absence of ongoing clinical failure; prolonged courses increase dysbiosis and may select for resistance [70]D5[76]B3b.
- Do not prescribe rifaximin alone for CDI; resistance is common (15.1% overall, 47% in RT027) [247]B2a (2a) and it is not guideline-endorsed.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Fidaxomicin vs vancomycin as first-line | IDSA/SHEA 2021, preferential use of fidaxomicin for initial CDI [1]A1c[2]A1c | ESCMID 2022, also recommends fidaxomicin as first-line, but vancomycin remains an appropriate alternative [223]D5 | Mild (both endorse fidaxomicin; difference in emphasis on cost) | In settings where fidaxomicin cost is prohibitive, vancomycin is a safe alternative; recurrence rates are higher but acceptable. |
| Duration with concomitant antibiotics | Expert consensus, consider extending CDI therapy (e.g., 10 days plus 5-7 days of concomitant antibiotic course) [70]D5 | IDSA/SHEA 2021, no duration adjustment recommended; extended therapy not supported by evidence [1]A1c[2]A1c | Moderate (lack of high-quality data) | Individualize: if concomitant antibiotics are required, some experts extend CDI treatment to cover the entire period of concomitant antibiotic use, but this is not guideline-recommended. |
Pearl: Fidaxomicin 200 mg twice daily for 10 days is the preferred first-line regimen for initial CDI; vancomycin is acceptable when fidaxomicin is unavailable. Shortened courses (5-7 days) can be considered in patients with prompt clinical response, and de-escalation of concomitant antibiotics is the single most impactful measure to prevent recurrence [1]A1c[2]A1c[38]B2b[70]D5.
| Drug | Dose | Route | Standard Duration | Key PK/PD | Level of Evidence |
|---|---|---|---|---|---|
| Fidaxomicin | 200 mg twice daily | Oral | 10 days | Minimal systemic absorption; high fecal concentrations; preserves microbiota | 1b [4]A1b[208]A1b |
| Vancomycin | 125 mg four times daily | Oral | 10 days | Not absorbed; high fecal concentrations; disrupts anaerobes | 1b [4]A1b[38]B2b |
| Metronidazole | 500 mg three times daily | IV | 10-14 days | Well absorbed; low fecal levels; inferior clinical cure | 1c [1]A1c[2]A1c |
| Bezlotoxumab | 10 mg/kg single dose | IV | - | Monoclonal antibody; neutralizes toxin B; adjunct to antibiotics | 1b [63]B2b[244]B2b |
| Tigecycline | Not standardized in CDI trials | IV | Variable | Moderate fecal concentrations; limited efficacy data | 2b [215]B2b |
History and Evolution of Treatment
- ▸First-line therapy evolved from metronidazole to vancomycin to fidaxomicin, which the IDSA/SHEA 2021 update recommends over vancomycin for initial episodes based on lower recurrence rates [1][2].
- ▸Microbiome-based therapies (SER-109, VE303) reduce recurrence by 60-70% relative to placebo in phase 3/2 trials, while FMT capsules showed no benefit in a recent placebo-controlled RCT [3][6][14].
- ▸Bezlotoxumab provides adjunctive recurrence reduction, and several narrow-spectrum investigational agents (ridinilazole, CRS3123, ibezapolstat) show promise in preserving microbiome diversity while targeting C. difficile [4][64][256].
As outlined in the preceding section, current definitive therapy rests on a foundation of randomized evidence that has evolved substantially over the past three decades, shifting from broad-spectrum to pathogen-directed and microbiome-sparing strategies.
From to to Fidaxomicin
Metronidazole was the first-line agent for mild-to-moderate CDI for decades, but accumulating evidence of inferior clinical cure and higher recurrence rates led to its abandonment as a preferred agent. By the 2010s, oral vancomycin became the standard comparator in trials, though recurrence rates remained 20-30% with vancomycin alone.
The landmark RCTs that established fidaxomicin as a superior first-line agent showed that fidaxomicin 200 mg twice daily for 10 days reduced recurrence by approximately half compared with vancomycin, with similar initial cure. The IDSA/SHEA 2021 focused update now recommends fidaxomicin over vancomycin for an initial episode of CDI (strong recommendation, moderate-quality evidence) [1]A1c[2]A1c. In the EXTEND trial, an extended-pulsed fidaxomicin regimen (twice daily days 1-5, then once daily on alternate days days 7-25) maintained stool concentrations above the MIC₉₀ through day 26, providing pharmacokinetic support for this approach [69]A1b. For patients receiving concomitant non-CDI antibiotics, a high-risk group, fidaxomicin showed numerically higher clinical cure than vancomycin (73% vs 62.9%) [208]A1b.
A vancomycin pulse-and-taper strategy has long been used empirically for recurrence prevention. A recent double-blind RCT of 265 patients found that a 4-week taper (125 mg twice daily for 7 days, then 125 mg once daily for 7 days, after a 2-week pulse) had a 73.8% posterior probability of superiority over a 2-week pulse alone for preventing recurrence at day 56, and a 99.0% probability at day 38 (adjusted RR 0.43, 95% CrI 0.19-0.89) [241]A1b. This provides the first randomized evidence supporting the taper approach.
The Microbiome Revolution: FMT and Defined Consortia
Recognition that recurrence is driven by persistent dysbiosis spurred microbiome-based therapies. Early (FMT) via achieved high success rates in uncontrolled series, but the first double-blind RCT of oral FMT capsules versus placebo in 153 veterans with recurrent CDI showed no benefit: the primary endpoint (recurrence or death by day 56) occurred in 32.9% of the FMT arm versus 29.9% of placebo (absolute difference 3.0%, 95% CI - to 17.7%), and the study was stopped for futility [3]A1b. By contrast, a cost-utility analysis of hospital-at-home with FMT in patients ≥70 years found it dominant, saving a mean €2556 per patient while reducing hospital days [251]B2c.
Defined microbiota therapeutics have produced clearer results. In the phase 3 ECOSPOR III trial, oral SER-109 (VOWST, purified Firmicutes spores) 4 capsules daily for 3 days after standard antibiotics reduced recurrence at week 8 to 12% versus 40% with placebo (RR 0.32, 95% CI 0.18-0.58; P < 0.001) [6]A1b. Subsequent analyses confirmed that SER-109 engrafted Firmicutes, depleted primary bile acids, and enriched secondary bile acids that inhibit C. difficile germination [242]B2b. VE303, an 8-strain consortium of commensal Clostridia, also showed a dose-dependent effect: recurrence at week 8 was 13.8% with the high dose versus 45.5% with placebo (P = 0.006) [14]A1b. REBYOTA (fecal microbiota, live-jslm) maintained response in 86% of patients who later received non-CDI antibiotics over 2 years [257]B2b.
Targeting Toxin: Bezlotoxumab and the Future
Bezlotoxumab, a monoclonal antibody against toxin B, emerged from the phase 3 MODIFY trials, in which it reduced recurrence by approximately 10% when added to standard antibiotics. Endogenous anti-toxin B antibodies are similarly protective: patients with high baseline titers had 22% recurrence versus 35% with low/medium titers [63]B2b. A matched cohort study comparing fidaxomicin monotherapy versus standard therapy plus bezlotoxumab found no significant difference in recurrence (19.3% vs 14.1%; OR 1.45, 95% after propensity matching) [258]B2b.
Investigational Horizons
Several novel agents aim to preserve the microbiome while selectively targeting C. difficile. Ridinilazole, a highly selective DNA synthesis inhibitor, did not meet superiority in sustained clinical response (73% vs 70.7%; treatment difference 2.2%, 95% CI -4.2% to 8.6%) but reduced recurrence by 53% relative to vancomycin (8.1% vs 17.3%;) and preserved microbiota diversity and secondary bile acids [4]A1b. CRS3123, an inhibitor of methionyl-tRNA synthetase, showed safety and minimal microbiome disruption in healthy volunteers, with fecal concentrations well above the MIC₉₀ [68]A1b; a phase 2 trial reported mild-to-moderate treatment-emergent adverse events and similar clinical cure to vancomycin [64]A1b. Ibezapolstat, a DNA polymerase IIIC inhibitor, achieved high stool concentrations with a distinct microbiome profile characterized by increased Actinobacteria, in contrast to the Proteobacteria expansion seen with vancomycin [256]A1b. DAV132, a colon-targeted adsorbent that binds intraluminal fluoroquinolones, preserved microbiota diversity and maintained ex vivo resistance to C. difficile colonization in hospitalized patients [255]A1b.
Attempts at active immunization have so far fallen short. The CLOVER phase 3 trial of a detoxified toxin A/B vaccine (PF-06425090) in 17,535 adults at increased risk did not meet its primary endpoint (vaccine efficacy 31.0%, 96.4% CI - to 66.6%), though it reduced symptom duration and need for CDI-related medical attention [62]A1b. Another toxoid vaccine trial was terminated after failing to show efficacy [65]A1b.
What Was Abandoned and Why
Metronidazole was abandoned as first-line therapy because of inferior cure and higher recurrence compared with vancomycin and fidaxomicin. Actoxumab, the anti-toxin A monoclonal antibody, lacked efficacy and was not pursued. Empirical extended vancomycin tapers, while widely used, had no randomized support until the 2026 taper trial [241]A1b. Routine FMT capsules, after the negative Veterans Health Administration trial [3]A1b, remain controversial; current guidelines prioritize defined microbiota therapeutics with proven phase 3 data.
These treatment advances have occurred in parallel with the emergence of antimicrobial resistance and the imperative for stewardship, the focus of the next section.
Pearl: Bezlotoxumab provides adjunctive recurrence reduction, and several narrow-spectrum investigational agents (ridinilazole, CRS3123, ibezapolstat) show promise in preserving microbiome diversity while targeting C. difficile [4]A1b[64]A1b[256]A1b.
| Agent/Strategy | Trial | Key Efficacy Result | Impact on Standard of Care |
|---|---|---|---|
| Fidaxomicin vs vancomycin | Multiple phase 3 trials | Recurrence ~15% vs ~25% | Recommended first-line per IDSA/SHEA 2021 [1]A1c[2]A1c |
| SER-109 (VOWST) | ECOSPOR III (2018) | Recurrence 12% vs 40% (RR 0.32, P<0.001) [6]A1b | FDA-approved for recurrent CDI |
| VE303 high dose | Phase 2 (2023) | Recurrence 13.8% vs 45.5% (P=0.006) [14]A1b | In phase 3 development |
| FMT capsules | VA RCT (2025) | Recurrence/death 32.9% vs 29.9% (NS) [3]A1b | Challenges routine FMT use |
| Vancomycin 4-week taper | Taper RCT (2026) | Day 56 recurrence 14.8% vs 17.7% (posterior prob 73.8%) [241]A1b | First RCT evidence for taper |
| Bezlotoxumab + SOC | MODIFY I/II (2016) | Recurrence ~16% vs ~26% (data in [63]B2b) | Adjunctive use in high-risk patients |
Antimicrobial Resistance and Stewardship
- ▸Resistance to fidaxomicin (via rpoB/rpoC mutations) and vancomycin (associated with RT 027 and RT 255) is emerging, with reduced susceptibility rates of 5.6% and 29%, respectively, in clinical isolates.
- ▸Antibiotic intensity, measured by the antibiotic spectrum index, is strongly associated with CDI risk, and β-lactam allergy labels increase the odds of C. difficile infection by 26%.
- ▸Microbiome-based therapies such as fecal microbiota transplantation reduce antimicrobial resistance gene abundance, offering a novel stewardship strategy.
The evolution of treatment has been paralleled by the emergence of antibiotic resistance in Clostridioides difficile, now listed as an urgent antimicrobial resistance threat by the CDC [24]D5. Understanding the mechanisms of resistance and the stewardship principles that preserve therapeutic efficacy is essential for maintaining control of this pathogen.
Resistance Mechanisms
Resistance to fidaxomicin, an RNA polymerase inhibitor, arises from mutations in the rpoB and rpoC genes encoding the β and β' subunits. The most common mutation, at position V1143 of the β subunit, accounts for approximately 50% of identified mutations, and about one-third of resistance mutations align directly with fidaxomicin-binding residues on the RNA polymerase [12]B2a. These mutations can emerge rapidly during therapy: a 38-year-old patient developed a fidaxomicin-resistant isolate (MIC 16 mg/L) after a single course of treatment, with a T3428G mutation in rpoB [77]C4. In a 3-year cohort, 5.6% of fidaxomicin-treated patients harbored isolates with reduced susceptibility (MICs 8-32 μg/mL), and genetically indistinguishable ribotype 097 strains with reduced susceptibility were transmitted between patients [73]B2b. Despite these findings, fidaxomicin resistance remains rare overall, and the high intestinal concentrations of the drug may mitigate clinical impact [12]B2a[73]B2b.
Reduced susceptibility is associated with specific ribotypes. In 594 isolates, 29% had vancomycin MIC >2 μg/mL, and RT 027 (odds ratio 13.4) and RT 255 (odds ratio 2.9) were independent risk factors for reduced susceptibility, whereas RT 014-020 was more likely to be susceptible [279]B3b. Vancomycin MICs are higher in RT 027 (MIC50: 2 μg/mL; MIC90: 2 μg/mL) than in non-RT027 isolates (MIC50: 0.5 μg/mL; MIC90: 1 μg/mL) [119]C4. No vanA or vanB genes have been detected, suggesting multifactorial mechanisms [176]B2b[119]C4. In a mouse model, vancomycin treatment failed to clear infection with a vancomycin-nonsusceptible isolate [176]B2b. Genomic surveillance of 26,557 C. difficile genomes found that putative resistance determinants for vancomycin are rare, but their frequency increased after 2000 and then declined recently, reflecting changes in [273]C4.
resistance is complex and multigenic. Chromosomal resistance can arise through epistasis between iron homeostasis and oxidoreductase pathways: truncation of the ferrous iron transporter FeoB1 is a first-step mechanism, followed by mutations in pyruvate-ferredoxin/flavodoxin oxidoreductase (PFOR, encoded by nifJ), xanthine dehydrogenase (xdh), and the iron-sulfur cluster regulator (iscR) [263]D5. The plasmid pCD-METRO, which confers metronidazole resistance, has been found in clinical and veterinary isolates in the Americas [196]C4. In a cohort of 438 patients from Houston, 29% had metronidazole-nonsusceptible isolates, and in Nairobi, 85% did [176]B2b.
C. difficile also produces a β-lactamase (BlaCDD) that is induced by β-lactam and dependent on the redox state of the enzyme; the bla operon is regulated by a conserved BlaRI system [272]D5. Resistance to is widespread in epidemic strains, particularly RT 027 (FQR1 and FQR2 lineages) and RT 017, and is linked to fluoroquinolone use [280]C4[89]C4. In Asia-Pacific isolates, moxifloxacin resistance exceeded 90% in RT 018 and RT 017 strains [89]C4. Clindamycin resistance is common, with 85.2% of Australian isolates resistant [95]C4. resistance has been reported in animal isolates carrying cfr(B) and cfr(C) genes on novel integrative conjugative elements [37]D5.
Multidrug-resistant (MDR) variants are defined as resistance to three or more antimicrobial classes. The prevalence of MDR has declined in some settings: in Sweden, the proportion of MDR isolates decreased by 80% from 2012 to 2016, coinciding with a 22% reduction in CDI incidence [54]B2c. In Australia, MDR prevalence was low at 1.7% [95]C4. However, emerging ribotypes such as RT 369 and QX 239 in Asia exhibit high rates of cross-resistance to moxifloxacin, erythromycin, and clindamycin [89]C4. The epidemic RT 027 strain remains the most strongly associated with severe outcomes and fluoroquinolone resistance, and its prevalence in Canada decreased from 2015 to 2022, replaced by RT 106 [53]B2c[153]B2c.
Stewardship Principles
Antibiotic exposure is the dominant modifiable risk factor for CDI. The antibiotic spectrum index (ASI) provides a granular measure of antibiotic intensity: each unit increase in ASI per antibiotic day was associated with a 1.09-fold increased risk of hospital-associated CDI (relative risk 1.09; 95%) [269]B2b. Cumulative antibiotic exposure prior to admission has a stronger association than inpatient exposure, with each day of therapy increasing odds by 12.8% [30]B2b. High-risk agents include second-generation and later cephalosporins, carbapenems, fluoroquinolones, and clindamycin, while and carry lower risk [30]B2b.
β-Lactam allergy labels (BALs) are a barrier to optimal antibiotic use. In a meta-analysis of 63 studies, BALs were associated with increased rates of infection or colonization with C. difficile and multidrug-resistant organisms [112]A1a. evaluation, including direct challenge for low-risk patients, can reduce unnecessary broad-spectrum antibiotic use [166]D5.
Carbapenem use is a marker for increased CDI risk. In patients with complicated intra-abdominal infections, empiric carbapenem treatment was associated with an odds ratio of 2.15 for CDI (95% CI 1.02-4.50) [79]B3b. Prospective audit and feedback interventions can reduce carbapenem consumption by 9% without increasing CDI rates [226]C4.
Selective decontamination of the digestive tract (SDD) with colistin, tobramycin, and nystatin reduced new C. difficile infections from 0.9% to 0.5% (absolute difference -0.24%) in mechanically ventilated patients [13]A1b. However, universal glove and gown use in ICUs did not reduce acquisition of toxigenic C. difficile [252]A1b, and adjunctive ultraviolet-C disinfection did not reduce CDI rates in cancer units [253]A1b.
Microbiome-based strategies are emerging as stewardship tools. (FMT) for recurrent CDI reduces antimicrobial resistance gene (ARG) abundance. In the ECOSPOR III trial, the microbiome therapeutic VOWST (fecal microbiota spores, live) led to a greater decline in ARG abundance by week 1 compared with placebo (P = 0.003), driven by depletion of Proteobacteria and repletion of spore-forming Firmicutes [266]A1b. In children, FMT also decreased ARG burden, though tetracycline resistance genes increased post-FMT [282]C4.
Ambulatory remains underdeveloped: only 7% of surveyed outpatient practices reported a fully functioning antimicrobial stewardship program, compared with 88% of inpatient settings [281]C4. The CDC Core Elements of Outpatient Antimicrobial Stewardship provide a framework for improvement.
Novel agents in the pipeline include ibezapolstat, a DNA polymerase IIIC inhibitor with potent activity against MDR strains (MIC50/90 4/8 μg/mL) [33]D5, and omadacycline, an aminomethylcycline with an MIC90 of 0.031 μg/mL against 250 clinical isolates [180]C4[183]C4. These agents may offer future options for treating resistant infections.
Pearl: The risk of hospital-associated CDI increases by 9% for each unit increase in antibiotic spectrum index per day of therapy; reducing antibiotic intensity is a measurable stewardship target [269]B2b.
| Antibiotic | Resistance Mechanism | Key Mutations/Genes | Clinical Impact |
|---|---|---|---|
| Fidaxomicin | RNA polymerase β/β' subunit mutations | V1143 (β subunit), rpoB T3428G, β' subunit binding-pocket residues | MICs 8-32 μg/mL; emergence on therapy and transmission documented [12]B2a[73]B2b[77]C4 |
| Vancomycin | Multifactorial; no vanA/B genes | Associated with ribotypes RT 027 and RT 255 | MIC50 2 μg/mL in RT 027; 29% isolates with MIC >2 μg/mL [119]C4[176]B2b[279]B3b |
| Metronidazole | Chromosomal (epistasis feoB1, nifJ, iscR); plasmid pCD-METRO | Truncation of FeoB1, PFOR mutations | 29% nonsusceptible in Houston, 85% in Nairobi [176]B2b[263]D5[196]C4 |
| β-Lactams | β-Lactamase (BlaCDD) induced by BlaRI system | bla operon, BlaRI regulatory genes | High-level resistance to ampicillin; redox-dependent activity [272]D5 |
| Moxifloxacin | DNA gyrase/topoisomerase IV mutations | gyrA, gyrB, parC | >90% resistance in RT 018, RT 017, RT 027 lineages [89]C4[280]C4 |
| Clindamycin | rRNA methylase (erm genes) | ermB | 85.2% resistance in Australian isolates [95]C4 |
| Linezolid | cfr(B) and cfr(C) on integrative conjugative elements | ICEs carrying cfr(B) or cfr(C) | High-level resistance in animal isolates; zoonotic potential [37]D5 |
Complications
- ▸ICU admission is the strongest predictor of adverse outcomes in CDI, with a >4-fold increased odds of MACE-CDI [288].
- ▸Vitamin K deficiency, though rare, can cause life-threatening coagulopathy and is rapidly reversible with 10 mg intravenous vitamin K [171].
- ▸Live biotherapeutic products have a favorable safety profile, with no severe drug-related adverse events in phase III trials [284].
The interplay between and CDI outcomes becomes starkly visible when complications arise, suboptimal therapy drives recurrence, while broad-spectrum alternatives carry their own toxicity.
Disease-Related Complications
Progression to severe or fulminant colitis occurs in a minority but drives mortality. ICU admission is associated with a 4.26-fold increased odds of MACE-CDI (composite of surgery, death, or complicated course) [288]B3b. In-hospital mortality reaches 13.8%, independently predicted by ICU admission (OR 8.89) and age ≥55 years [288]B3b. Respiratory failure may require mechanical ventilation; FVC thresholds <15 mL/kg should prompt intubation, extrapolated from neuromuscular disease protocols. Autonomic instability (ileus, hypotension, arrhythmias) necessitates continuous monitoring. Vitamin K deficiency, though rare, can cause INR >8; high-dose intravenous vitamin K (10 mg) corrects within 24 hours [171]C4.
Iatrogenic and Hospital-Acquired Complications
VRE colonization in ICU/IMC patients with CDI confers a >16-fold increased risk of adverse outcomes [288]B3b. Parenteral nutrition and are independently associated with severe CDI and prolonged hospitalization [288]B3b. Antibiotic-associated CDI complicates other therapies: versus doubles CDI risk (0.04% vs 0.02%; RR 2.14) [28]B2b. Unverified beta-lactam allergy labels increase CDI risk [112]A1a. FMT and microbiota-based products carry low infectious risk: donor-derived Escherichia coli infections occurred in 2/75 non-CDI recipients (4.0%) and serious adverse reactions in 1.9% of rCDI recipients [26]B2b. FDA-approved products have no severe drug-related events reported [284]D5.
Prevention and
VTE prophylaxis with low-molecular-weight (e.g., 40 mg subcutaneously daily) is standard unless contraindicated by coagulopathy or active bleeding. Pain management should avoid opioids that further slow transit; acetaminophen is preferred, with NSAIDs reserved for non-coagulopathic patients. Early mobilization and nutrition support reduce hospital-acquired complications. Avoid unnecessary PPIs; RCT meta-analysis found no increased CDI risk (OR 1.29) [287]A1a, opposing observational concerns.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| MACE-CDI (surgery, death, complicated course) | 16.1% [288]B3b | Early severe CDI recognition, appropriate antibiotic selection | ICU support, surgical consultation for toxic megacolon/perforation |
| In-hospital mortality | 13.8% [288]B3b | ICU triage, source control | Supportive care, treat underlying comorbidity |
| CDI recurrence after taper | 14.8% at 56 days [241]A1b | Extended vancomycin pulse/taper (4-week regimen) [241]A1b | Fidaxomicin, microbiota-based therapy (FMT, RBL, SER-109) |
| VRE colonization in ICU CDI | >16-fold risk [288]B3b | Antimicrobial stewardship, contact precautions | Avoid unnecessary , consider targeted decolonization |
| Vitamin K deficiency coagulopathy | Rare | Screen in malnourished/elderly | IV vitamin K 10 mg [171]C4 |
| Donor-derived infection from FMT | <2% in rCDI (1.9% SAR) [26]B2b | Rigorous donor screening [26]B2b | Antibiotic therapy guided by susceptibility |
Pearl: In elderly, malnourished, or critically ill CDI patients with unexplained coagulopathy, suspect vitamin K deficiency and treat empirically with 10 mg intravenous vitamin K while awaiting confirmatory testing [171]C4.
Prognosis and Natural History
- ▸Asymptomatic C. difficile carriage progresses to CDI in 13.4% of healthcare-acquired cases; most carriage is transient.
- ▸NAP1/BI/R027 strains are associated with a near-doubling of recurrence and attributable mortality, while eosinopenia plus binary toxin confers an OR of 7.8 for inpatient death.
- ▸Fidaxomicin reduces composite failure by 72% in immunocompromised patients, and FMT reduces recurrence and mortality in recurrent disease.
The natural history of CDI spans a spectrum from asymptomatic carriage to fulminant colitis, with outcomes shaped by host factors, strain virulence, and treatment choice. Among patients acquiring toxigenic C. difficile in healthcare settings, 9.9% become asymptomatic carriers and 13.4% of those progress to CDI; most carriage is transient (61.0%), with a median 77 days to clearance [175]B2b. Cases testing NAAT-positive but toxin-negative have 30-day all‑cause mortality of 6.7% versus 8.4% for NAAT‑positive/toxin‑positive (risk difference 0.41%, 95% CI -0.67 to 1.49), but treatment of NAAT‑positive/toxin‑negative patients reduces mortality (RD -, 95% CI -12.29 to -2.60) without affecting recurrence [61]B2a. Recurrence at 60 days is significantly higher when toxin is detected (19.8% vs 11.0%; RD 7.65%, 95% CI 4.60-10.71) [61]B2a.
Predictors of Poor Outcomes
Strain type strongly modifies prognosis. The NAP1/BI/R027 ribotype is associated with higher recurrence (pooled RR 1.98), intensive‑care admission, , or CDI‑attributable death (RR 1.88), and 30‑day attributable mortality (RR 1.96) [78]B2a. Attributable mortality grades from 1.7% for R014/20 to 10.2% for R027 [78]B2a. The combination of peripheral eosinopenia (0.0 cells/μL) and infection with a binary toxin‑producing strain independently predicts inpatient mortality (OR 7.8) [100]B3b. Meta‑analyses of risk factors identify older age, antibiotic use, proton‑pump inhibitors, and inflammatory bowel disease as predictors of recurrence; immunosuppression, elevated WBC, Charlson Comorbidity Index, blood urea nitrogen, and creatinine predict mortality [124]A1a.
| Predictor | Outcome | Effect Estimate | Source |
|---|---|---|---|
| Immunosuppression | Mortality | OR 1.83 (95% CI 1.28-2.63) | [124]A1a |
Treated Outcomes
With optimal therapy, primary cure rates exceed 80% but recurrence remains a challenge. A 4‑week pulse‑and‑taper regimen reduced 38‑day recurrence to 6.7% versus 15.4% with a 2‑week pulse (adjusted RR 0.43, 95% CrI 0.19-0.89; posterior probability of superiority 99.0%) [241]A1b. In immunocompromised patients, fidaxomicin compared with vancomycin decreased the composite of clinical failure, 30‑day relapse, or CDI‑related death (HR 0.28, 95% CI 0.08-0.93) and reduced the combined risk of 30‑ and 90‑day relapse by 70% [303]B2b. (FMT) for recurrent CDI yields 82.8% response at 8 weeks with 88.7% sustained through 6 months [228]C4; in a propensity‑matched cohort, FMT reduced recurrence (OR 0.6) and mortality (OR 0.26, 95% CI 0.08-0.82) [229]B2b.
Long‑term Burden
One‑year attributable mortality among Medicare Advantage enrollees is 7.9% (CDI cases 26.3% vs controls 18.4%) [295]B3b. Hospital‑onset CDI carries 30‑day rehospitalization rates of 9.5% and 1‑year attributable costs of $14,257 [294]B3b[301]B2b. Community‑associated CDI shows 180‑day mortality of 66.3% versus 12.3% in matched controls [301]B2b.
Pearl: The combination of eosinopenia and binary‑toxin strain at diagnosis multiplies mortality risk nearly 8‑fold, a readily available can identify this high‑risk subset at the bedside [100]B3b.
Prevention and Infection Control
- ▸Contact precautions and sporicidal disinfection remain standard, though universal gloving and UV-C light have not demonstrated added benefit in trials.
- ▸Targeted oral vancomycin prophylaxis can reduce CDI in high-risk patients (prior CDI, immunocompromised) during systemic antibiotic exposure, but may increase VRE carriage.
- ▸No vaccine is approved; current prevention relies on antimicrobial stewardship, infection control, and risk-stratified prophylaxis.
Given that up to one-third of patients experience recurrent CDI, prevention strategies target both primary infection in at-risk populations and recurrence after treatment.
Environmental and Contact Precautions
Contact precautions (gloves and gowns) for all patient contact remain standard for symptomatic patients, but universal gloving in ICUs did not reduce C. difficile acquisition (rate difference -0.28 per 100 patient-days) in a cluster-randomized trial [252]A1b. Environmental disinfection with sporicidal agents (e.g., chlorine-based products, ortho-phthalaldehyde) reduces surface contamination, yet no disinfectant completely eliminates C. difficile from biofilms [35]D5. Adjunctive ultraviolet-C (UV-C) light added no benefit for CDI rates (IRR 1.43; 95% CI 0.93-2.21) [253]A1b. The pandemic saw a 20% reduction in CDI incidence (pooled IRR 0.80), attributed to enhanced hand hygiene and [126]A1a.
Antimicrobial Stewardship and Prophylaxis
Judicious antibiotic prescribing remains the most impactful prevention strategy. Primary prophylaxis with oral (125 mg once daily during systemic plus 5 days post) reduced healthcare facility-onset CDI from 12% to 0% (P =.03) in a small randomized trial [304]A1b. In autologous stem cell transplant recipients, OVP (125 mg twice daily from admission to discharge) reduced in-hospital CDI from 11% to 4% (P =.03) [150]B2b. Secondary prophylaxis during antibiotic re-exposure in patients with prior CDI shows a trend toward fewer recurrences (43.6% vs 57.1%; absolute difference -13.5%; underpowered), but increased vancomycin-resistant Enterococcus carriage (50% vs 24%) [313]A1b. In pediatric cancer, secondary OVP significantly reduced recurrence (aOR 0.074) [312]B2b. Probiotic data are mixed: Saccharomyces boulardii co-administered within 24 h of antibiotics reduced HO-CDI (OR 0.47) [309]B2b, but a multicenter probiotic decision-support intervention did not reduce CDI (OR 1.46) [306]B2b. Proton pump inhibitors for stress ulcer prophylaxis do not increase CDI risk in RCT-level meta-analyses (OR 1.29) [287]A1a and are recommended when clinically indicated [254]A1b.
Vaccine Development
No C. difficile vaccine is licensed. Natural toxin immunization occurs in colonized infants, who develop antitoxin IgA/IgG and neutralizing antibodies [72]B2b. Several vaccine candidates targeting toxins A/B are in development but none have completed pivotal trials [218]D5.
Patient Education
Handwashing with soap and water (alcohol-based sanitizers are less effective against spores) and designated bathroom cleaning with sporicidal wipes are recommended for patients recovering at home. Transmission to household contacts is uncommon [212]D5.
Pearl: The single most effective prevention strategy is antimicrobial stewardship, any antibiotic prescribed is an opportunity to reconsider necessity and spectrum, as even one dose can trigger CDI in a colonized host.
Special Hosts and Populations
- ▸Pediatric CDI is predominantly community-associated; diagnosis requires distinguishing colonization from infection, especially in infants, where fecal calprotectin >500 µg/g may help.
- ▸In immunocompromised hosts (HCT, SOT, cancer), metronidazole should be avoided due to a doubled recurrence risk; fidaxomicin and FMT are safe and effective options, with FMT achieving 87.4% resolution after consecutive treatments.
- ▸Antibiotic stewardship in special populations, such as individualized antibiotic plans in pediatric HCT and risk-adapted fluoroquinolone prophylaxis in hematology, reduces unnecessary antibiotic exposure without increasing CDI rates.
While prevention and infection control measures apply broadly, the risk, presentation, and optimal of CDI are uniquely shaped by host factors, age, immune status, and organ dysfunction, demanding population-specific strategies.
Pediatric Population
Pediatric CDI has distinct and diagnostic challenges. Community-associated CDI incidence is three times higher than healthcare facility-associated CDI in children, though sources of community acquisition remain poorly defined [330]D5. In Canadian surveillance (2015-2022), pediatric healthcare-associated CDI rates declined by 29.6% and community-associated rates by 58.3%; ribotype 106 supplanted RT027 as the predominant strain [53]B2c. Diagnosis is complicated by high rates of asymptomatic colonization, particularly in infants, making it difficult to distinguish active infection from carriage [330]D5. Fecal calprotectin >500 µg/g shows high specificity for CDI in children and predicts recurrence risk, offering a host-focused adjunct to conventional testing [328]D5.
Treatment trials specific to children support a shift away from . The SUNSHINE phase 3 trial randomized 148 patients (<18 years) to fidaxomicin (twice daily) or (four times daily) for 10 days [317]A1b. Clinical response 2 days after therapy was 77.6% with fidaxomicin versus 70.5% with vancomycin; global cure at 30 days was significantly higher with fidaxomicin (68.4% vs 50.0%; adjusted treatment difference, 18.8%; 95% CI, 1.5%-) [317]A1b. No treatment-related deaths occurred, and systemic absorption was minimal with high stool concentrations [317]A1b. Current guidelines now recommend vancomycin as first-line therapy for initial pediatric CDI, with fidaxomicin reserved for recurrent disease, and (FMT) is safe and effective for multiply recurrent cases [325]A1c[330]D5. In pediatric oncology and hematopoietic cell transplant (HCT) recipients, whole-genome sequencing reveals highly diverse C. difficile isolates, with >70% of new CDI episodes representing recurrences of a prior strain rather than reinfection [318]B2b. interventions, such as individualized antibiotic plans (IAPs), reduce overall antibiotic use without increasing CDI test positivity rates in this high-risk population [311]C4.
Immunocompromised Hosts (HCT, Solid Organ Transplant, Cancer, HIV)
Immunocompromised patients face higher risks of severe and recurrent CDI. Among adult HCT recipients, the cumulative incidence of recurrent CDI within 12 weeks of index infection is 10% (95% CI, 7-13%) [148]B2b. Metronidazole monotherapy for the index episode is associated with a doubled rate of recurrence (adjusted HR 2.0; 95% CI, 1.0-4.0;), confirming that metronidazole should be avoided in these patients [148]B2b[325]A1c. Fidaxomicin is an appropriate alternative; in the SUNSHINE trial, the pediatric subgroup included oncology patients and showed favorable safety [317]A1b.
FMT is emerging as a safe and effective option for recurrent CDI in immunocompromised individuals. A meta-analysis of 44 studies including 1208 immunocompromised patients (solid organ transplant, n = 219; cancer on chemotherapy, n = 101; HCT, n = 29; advanced HIV, n = 11) showed clinical resolution after a single FMT of 75.3% (95% CI, 71.7%-78.6%), rising to 87.4% (95% CI, 84.8%-89.6%) with consecutive treatments [326]C4. The recurrence rate was 23.9%, and serious adverse events occurred in 10.1%, comparable to rates in immunocompetent populations [326]C4. These data support the use of FMT in mild to moderately immunocompromised hosts without contraindication based on immunosuppression alone.
Fluoroquinolone prophylaxis (FQP) in hematological malignancy and HCT requires careful risk-benefit assessment. While FQP consistently reduces febrile neutropenia and bloodstream infections, its benefit is diminished in allogeneic HCT and in settings with background fluoroquinolone resistance ≥30% [278]D5. Baseline gut colonization with fluoroquinolone-resistant Enterobacterales further attenuates efficacy. Importantly, FQP does not significantly increase CDI risk (odds ratio 0.43; 95% CI, 0.00-42.30 in pediatric acute lymphoblastic leukemia; not significant) [125]B2a[278]D5. Current guidance advocates a risk-adapted, individualized approach rather than universal prophylaxis, embedded within antimicrobial stewardship programs [327]D5.
Diagnostic stewardship is critical in immunocompromised hosts, where diarrhea has a broad differential. Multiplexed PCR panels identify infectious etiologies in a higher proportion of HCT recipients than conventional testing (37% vs 25%; P = 0.01), with enteropathogenic E. coli, norovirus, and Yersinia enterocolitica being common non-C. difficile pathogens [322]C4. Costs do not increase, making multiplex PCR a valuable tool to avoid unnecessary CDI overtreatment [322]C4[329]D5.
End-Stage Renal Disease (ESRD)
Patients with ESRD have high rates of antibiotic exposure, predisposing them to CDI. An analysis of Medicare Part D claims in New York State (2016-2017) found that ESRD patients received at a rate of 520.29 per 1000 patients versus 296.48 per 1000 in non-ESRD patients, with prescription incidence of 1359.95 per 1000 versus 673.61 per 1000 [323]B3b. In 36% of cases, dosages exceeded current ESRD guideline recommendations, highlighting an opportunity for antibiotic stewardship [323]B3b. While specific CDI outcome data in this population are limited, the high antibiotic burden underscores the importance of minimizing unnecessary antimicrobial use.
Other Host Considerations
Elderly patients are disproportionately affected by severe CDI. In a large U.S. surveillance study, 48.2% of toxin-positive cases occurred in patients ≥65 years versus 38.0% of NAAT-positive-only cases, and toxin positivity itself was independently associated with recurrence (adjusted OR 1.89; 95% CI, 1.61-2.23) [163]B3b. Age-related declines in immune function and gut microbiome resilience likely contribute.
Pregnancy: data are sparse, but given physiological changes in immunity and microbiome during pregnancy, CDI may present atypically. No specific prospective trials exist in this population; management follows adult guidelines with careful consideration of fetal safety for antimicrobial choices.
Pearl: In immunocompromised patients with recurrent CDI, fecal microbiota transplantation achieves a clinical resolution rate of 87.4% with consecutive treatments, comparable to immunocompetent populations, and should not be withheld due to immunosuppression alone [326]C4.
| Outcome | Single FMT | Consecutive FMTs |
|---|---|---|
| Recurrence | 23.9% | - |
| Serious adverse events | 10.1% | - |
Data from meta-analysis of 44 studies including 1208 immunocompromised patients [326]C4
References
- [1]
Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34164674 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [2]
Johnson S, Lavergne V, Skinner AM et al.. “Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 34492699 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [3]
Drekonja DM, Shaukat A, Huang Y et al.. “A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39271107 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [4]
Okhuysen PC, Ramesh MS, Louie T et al.. “A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38305378 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [5]
Feuerstadt P, Chopra T, Knapple W et al.. “PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39180326 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Complications - [6]
Feuerstadt P, Louie TJ, Lashner B et al.. “SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.” The New England journal of medicine (2022). PMID: 35045228 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [7]
Dubberke ER, Puckett JT, Obi EN et al.. “Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes.” Open forum infectious diseases (2022). PMID: 36267250 ↗
L3GUIDELINECited in: Definition, Classification and Causative Organisms - [8]
Beniwal-Patel P, Stein DJ, Munoz-Price LS. “The Juncture Between Clostridioides difficile Infection and Inflammatory Bowel Diseases.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30689770 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications - [9]
Alshannaq AF, Kates AE, Keating JA et al.. “Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39215602 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [10]
Lavoie T, Appaneal HJ, LaPlante KL. “Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051964 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [11]
Anderson SM, Sears CL. “The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051969 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Prognosis and Natural History - [12]
Le TM, Eubank TA, McKelvey AM et al.. “Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.” Antimicrobial agents and chemotherapy (2024). PMID: 39503488 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [13]
Myburgh JA, Seppelt IM, Goodman F et al.. “Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial.” JAMA (2022). PMID: 36286097 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [14]
Louie T, Golan Y, Khanna S et al.. “VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA (2023). PMID: 37060545 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [15]
Khanna S, Allegretti JR, Hashash JG et al.. “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.” Gastroenterology (2026). PMID: 42138670 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prevention and Infection Control - [16]
Jo J, Carlson TJ, Hu C et al.. “Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.” The Journal of antimicrobial chemotherapy (2025). PMID: 40796204 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [17]
Di Bella S, Sanson G, Monticelli J et al.. “Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.” Clinical microbiology reviews (2024). PMID: 38421181 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [18]
Yadegar A, Bar-Yoseph H, Monaghan TM et al.. “Fecal microbiota transplantation: current challenges and future landscapes.” Clinical microbiology reviews (2024). PMID: 38717124 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [19]
Beebe MA, Sorg JA. “An update on Clostridioides difficile population structure and genomics.” Clinical microbiology reviews (2026). PMID: 41914740 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [20]
Tang L, Xie P, Wang H et al.. “The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions.” Clinical microbiology reviews (2025). PMID: 41263574 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [21]
Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [22]
Veve MP, Kenney RM, Aljundi AM et al.. “Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.” Antimicrobial agents and chemotherapy (2025). PMID: 40035548 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History, Special Hosts and Populations - [23]
DeFilipp Z, Bloom PP, Torres Soto M et al.. “Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.” The New England journal of medicine (2019). PMID: 31665575 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Complications - [24]
Butler MS, Gigante V, Sati H et al.. “Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.” Antimicrobial agents and chemotherapy (2022). PMID: 35007139 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [25]
Rode AA, Duboc H, Lamazière A et al.. “Re-establishing bile acid composition after treatment of recurrent Clostridioides difficile infection with fecal microbiota transplantation compared with oral vancomycin or a 12-strain bacterial mixture.” Gut microbes (2026). PMID: 41997890 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [26]
Chernova VO, van Prehn J, Groenewegen B et al.. “Biovigilance in Faecal Microbiota Transplantation: 7-Year Cohort Study and Framework for Microbiological Assessments of Infectious Adverse Events.” United European gastroenterology journal (2026). PMID: 42283215 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications - [27]
Duricek M, Bartos H, Halmova K et al.. “ESBL positivity as an independent predictor of Clostridioides difficile infection: a retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42070626 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [28]
Savage TJ, Butler AM, Kronman MP et al.. “Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults.” JAMA (2026). PMID: 41999289 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History - [29]
Gong J-J, Huang I-H, Hung Y et al.. “Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.” Antimicrobial agents and chemotherapy (2025). PMID: 40525407 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [30]
Webb BJ, Subramanian A, Lopansri B et al.. “Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.” Antimicrobial agents and chemotherapy (2020). PMID: 31964789 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [31]
Madden GR, Petri WA, Costa DVS et al.. “Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.” Antimicrobial agents and chemotherapy (2022). PMID: 35727061 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [32]
Kester JC, Brubaker DK, Velazquez J et al.. “Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.” Antimicrobial agents and chemotherapy (2020). PMID: 31988098 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [33]
Bassères E, Eubank TA, Begum K et al.. “Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.” Antimicrobial agents and chemotherapy (2024). PMID: 38364016 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [34]
Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 31932379 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [35]
Rashid T, Haghighi F, Hasan I et al.. “Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms.” Antimicrobial agents and chemotherapy (2019). PMID: 31611365 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prevention and Infection Control - [36]
Buckley AM, Moura IB, Altringham J et al.. “The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection.” The Journal of antimicrobial chemotherapy (2021). PMID: 34561709 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment - [37]
Brenciani A, Massacci FR, Albini E et al.. “Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy.” The Journal of antimicrobial chemotherapy (2025). PMID: 40556560 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [38]
Duricek M, Halmova K, Krutova M et al.. “Is shorter also better in the treatment of Clostridioides difficile infection?” The Journal of antimicrobial chemotherapy (2024). PMID: 38661207 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [39]
Ranganath N, Tabaja H, Nair VO et al.. “Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40470775 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [40]
Schwanbeck J, Riedel T, Laukien F et al.. “Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.” The Journal of antimicrobial chemotherapy (2019). PMID: 30247587 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup - [41]
Saydan S, Schwab F, Holstiege J et al.. “Surveillance of Clostridioides difficile on hospital admission and outpatient antibiotic use in Germany-a 9 year ecological analysis.” The Journal of antimicrobial chemotherapy (2025). PMID: 39821312 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [42]
Eyre DW, Shaw R, Adams H et al.. “WGS to determine the extent of Clostridioides difficile transmission in a high incidence setting in North Wales in 2015.” The Journal of antimicrobial chemotherapy (2019). PMID: 30561656 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, History and Evolution of Treatment - [43]
Orzechowski D, Mroczkowska A, Bryła A et al.. “Clinical Considerations of Amikacin Pharmacotherapy in Adults-A Narrative Review with Focus on Safety and TDM.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353658 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [44]
Lietz S, Barth H. “Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin.” Archives of toxicology (2026). PMID: 41991729 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis - [45]
Boton N, Patel PK, Beekmann SE et al.. “Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey.” Open forum infectious diseases (2025). PMID: 40599494 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [46]
Dubberke ER, Li Q, Obi EN et al.. “A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 39355263 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [47]
Jitmuang A, Lertlaksameewilai P, Poorichitiporn A et al.. “Multiplex Gastrointestinal Panel Testing in Hospitalized Patients With Acute Diarrhea in Thailand.” Open forum infectious diseases (2024). PMID: 38962524 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis - [48]
Chua HC, Eubank TA, Lee A et al.. “Defining Fulminant Clostridioides difficile Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion.” Open forum infectious diseases (2025). PMID: 39896986 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [49]
Carlson TJ, Gonzales-Luna AJ, Nebo K et al.. “Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection.” Open forum infectious diseases (2020). PMID: 33209956 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [50]
Yin J, Kociolek LK, Same RG et al.. “Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections.” Open forum infectious diseases (2019). PMID: 31950069 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms - [51]
Skinner AM, Petrella L, Siddiqui F et al.. “Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain.” Emerging infectious diseases (2020). PMID: 31961290 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [52]
Conlon-Bingham GM, Aldeyab M, Scott M et al.. “Effects of Antibiotic Cycling Policy on Incidence of Healthcare-Associated MRSA and Clostridioides difficile Infection in Secondary Healthcare Settings.” Emerging infectious diseases (2019). PMID: 30561306 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [53]
Du T, Silva A, Choi KB et al.. “Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015-2022.” Emerging infectious diseases (2025). PMID: 40439410 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [54]
Rizzardi K, Norén T, Aspevall O et al.. “National Surveillance for Clostridioides difficile Infection, Sweden, 2009-2016.” Emerging infectious diseases (2018). PMID: 30124193 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [55]
Kim MH, Kim J, Ra H et al.. “Identifying Contact Time Required for Secondary Transmission of Clostridioides difficile Infections by Using Real-Time Locating System.” Emerging infectious diseases (2024). PMID: 38666567 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [56]
Sandhu A, Tillotson G, Polistico J et al.. “Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.” Emerging infectious diseases (2020). PMID: 32441243 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [57]
Zambelli G, Masetti M, Rasmi S et al.. “Restoring Microbial Balance: Clinical Applications, Challenges, and Future Directions of Fecal Microbiota Transplantation in Pediatric Disorders.” Microorganisms (2026). PMID: 42354867 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [58]
Raphaël É, Huynh S, Blez D et al.. “Ceftriaxone versus cefotaxime: a scoping review of resistance selection, Clostridioides difficile risk, economic implications and environmental impacts.” Infectious diseases now (2026). PMID: 42013917 ↗
L2REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [59]
Bayode MT, Olawale OE, Olusola-Makinde OO. “Divergent mechanistic pathways of diarrheagenic bacterial infections at the host-microbiota interface: a review.” Archives of microbiology (2026). PMID: 42007992 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis - [60]
Patel MJ, O'Brien J. “Epidemiologic Trends in Clostridioides difficile Infection Among U.S. Emergency Department Patients, 2014-2024.” American journal of infection control (2026). PMID: 42431317 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [61]
Prosty C, Hanula R, Katergi K et al.. “Clinical Outcomes and Management of NAAT-Positive/Toxin-Negative Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37648251 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [62]
Donskey CJ, Dubberke ER, Klein NP et al.. “CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39180325 ↗
L1RCTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [63]
Kelly CP, Poxton IR, Shen J et al.. “Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31628838 ↗
L2RCTCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [64]
Louie T, Ribble W, Boccumini L et al.. “Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.” The Lancet. Infectious diseases (2026). PMID: 41581516 ↗
L1RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [65]
de Bruyn G, Gordon DL, Steiner T et al.. “Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.” The Lancet. Infectious diseases (2020). PMID: 32946836 ↗
L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications, Prognosis and Natural History - [66]
Edlund C, Ternhag A, Skoog Ståhlgren G et al.. “The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.” The Lancet. Infectious diseases (2021). PMID: 34756180 ↗
L1RCTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [67]
Karlowsky JA, Steenbergen J, Zhanel GG. “Microbiology and Preclinical Review of Omadacycline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367743 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [68]
Lomeli BK, Galbraith H, Schettler J et al.. “Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.” Antimicrobial agents and chemotherapy (2019). PMID: 31685472 ↗
L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications - [69]
Guery B, Georgopali A, Karas A et al.. “Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.” The Journal of antimicrobial chemotherapy (2020). PMID: 31960058 ↗
L1RCTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment - [70]
Fitzpatrick F, Safdar N, van Prehn J et al.. “How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?” The Lancet. Infectious diseases (2022). PMID: 35617982 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [71]
Jo J, Hu C, Horvath TD et al.. “Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin.” Antimicrobial agents and chemotherapy (2025). PMID: 39819014 ↗
L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis - [72]
Kociolek LK, Espinosa RO, Gerding DN et al.. “Natural Clostridioides difficile Toxin Immunization in Colonized Infants.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31253983 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Complications, Prevention and Infection Control - [73]
Redmond SN, Cadnum JL, Jencson AL et al.. “Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036727 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [74]
Lin Q, Pollock NR, Banz A et al.. “Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31400280 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [75]
Villafuerte Gálvez JA, Pollock NR, Alonso CD et al.. “Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35906836 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Complications - [76]
Schechner V, Fallach N, Braun T et al.. “Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study.” The Journal of antimicrobial chemotherapy (2021). PMID: 33969419 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [77]
Marchandin H, Anjou C, Poulen G et al.. “In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2023). PMID: 37352110 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship - [78]
Abou Chakra CN, Gagnon A, Lapointe S et al.. “The Strain and the Clinical Outcome of Clostridioides difficile Infection: A Meta-analysis.” Open forum infectious diseases (2024). PMID: 38524230 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [79]
Zilberberg MD, Nathanson BH, Ditch K et al.. “Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort Study.” Open forum infectious diseases (2019). PMID: 31858017 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [80]
Nichols WW, Bradford PA, Stone GG. “The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.” The Journal of antimicrobial chemotherapy (2023). PMID: 36883356 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [81]
Wilcox MH, McGovern BH, Hecht GA. “The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.” Open forum infectious diseases (2020). PMID: 32405509 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Complications - [82]
Bansal D, Pahil S, Chatterjee A et al.. “Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.” Therapeutic advances in gastroenterology (2026). PMID: 42136876 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis - [83]
Wondimkun YA, Inacio MC, Lekkas P et al.. “Trends in microbiology testing in Australian long-term care facilities: national cohort study.” BMC infectious diseases (2026). PMID: 42226143 ↗
L4COHORTCited in: Microbiology and Pathogenesis - [84]
Lee SH, Kim TY, Huh HJ et al.. “Clinical outcomes of toxin-positive versus toxin-negative/NAAT-positive Clostridioides difficile infection in South Korea: a single-center retrospective cohort study.” BMC infectious diseases (2026). PMID: 42168920 ↗
L3COHORTCited in: Microbiology and Pathogenesis - [85]
Liu Y, Ma L, Cheng J et al.. “Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms.” Antimicrobial agents and chemotherapy (2023). PMID: 37223895 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [86]
Costa DVS, Pham NVS, Hays RA et al.. “Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35861541 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification - [87]
Kaple CE, Redmond SN, Cadnum JL et al.. “Clinical failure of an extended-pulsed fidaxomicin regimen associated with emergence of a Clostridioides difficile isolate with reduced fidaxomicin susceptibility in an elderly man.” Antimicrobial agents and chemotherapy (2026). PMID: 42080560 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [88]
Abutaleb NS, Seleem MN. “Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32253206 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [89]
Lew T, Putsathit P, Sohn KM et al.. “Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.” Antimicrobial agents and chemotherapy (2020). PMID: 32393487 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [90]
Harris HC, Best EL, Normington C et al.. “Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics.” Antimicrobial agents and chemotherapy (2020). PMID: 33139292 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [91]
Budi N, Godfrey JJ, Safdar N et al.. “Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile.” Antimicrobial agents and chemotherapy (2021). PMID: 33649111 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [92]
Thorpe CM, McDermott LA, Tran MK et al.. “U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.” Antimicrobial agents and chemotherapy (2019). PMID: 31085514 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [93]
Aoki K, Takeda S, Miki T et al.. “Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.” Antimicrobial agents and chemotherapy (2019). PMID: 31527041 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [94]
Hutton ML, Pehlivanoglu H, Vidor CJ et al.. “Repurposing auranofin as a Clostridioides difficile therapeutic.” The Journal of antimicrobial chemotherapy (2020). PMID: 31642901 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [95]
Putsathit P, Hong S, George N et al.. “Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.” The Journal of antimicrobial chemotherapy (2021). PMID: 33895826 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [96]
Murray B, Wolfe C, Marra A et al.. “In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32285102 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [97]
Escudero-Sánchez R, Rubio Martín E, Vizcarra P et al.. “Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36861316 ↗
L3OTHERCited in: Microbiology and Pathogenesis - [98]
Simpson M, Bilverstone T, Leslie J et al.. “Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model.” Open forum infectious diseases (2023). PMID: 36895287 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [99]
Young MK, Leslie JL, Madden GR et al.. “Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease.” Open forum infectious diseases (2022). PMID: 35146046 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [100]
Carlson TJ, Endres BT, Le Pham J et al.. “Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2020). PMID: 31993458 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [101]
Anderson SM, Cing Z, Drewes JL et al.. “Clostridioides difficile Detection in a Human CRC Cohort.” Open forum infectious diseases (2026). PMID: 41969757 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [102]
Hilt EE, Vaughn BP, Galdys AL et al.. “Impact of the Reverse 2-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients.” Open forum infectious diseases (2024). PMID: 38756762 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [103]
Jorgensen SCJ, Trinh TD, Zasowski EJ et al.. “Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.” Open forum infectious diseases (2019). PMID: 31890725 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations - [104]
Wilcox MH, Cornely OA, Guery B et al.. “Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.” Open forum infectious diseases (2019). PMID: 31723569 ↗
L1OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation - [105]
Pender M, Throneberry SK, Grisel N et al.. “Syndromic Panel Testing Among Patients With Infectious Diarrhea: The Challenge of Interpreting Clostridioides difficile Positivity on a Multiplex Molecular Panel.” Open forum infectious diseases (2023). PMID: 37711280 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [106]
Widmer AF, Frei R, Kuijper EJ et al.. “Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland.” Emerging infectious diseases (2020). PMID: 32946368 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [107]
Iorgoni V, Stanga L, Nistor P et al.. “Fatal Systemic Infection Caused by Multidrug-Resistant Clostridioides difficile in a Domestic Rabbit: A Comprehensive Case Analysis.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353696 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [108]
Wu L, Li Z, Zhu J et al.. “Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.” Microorganisms (2026). PMID: 42354799 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [109]
Mirjalili S, Hosseini Hooshiar M, Abbasabadarabi S et al.. “Host immunity and recurrent Clostridioides difficile infection: a comprehensive review.” Pathogens and global health (2026). PMID: 42304879 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [110]
Zhao M, Wen B, Ouyang Z et al.. “Parabacteroides distasonis alleviates Clostridioides difficile infection in mice while modulating secondary bile acids.” Virulence (2026). PMID: 42402046 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [111]
Queraltó C, Rodríguez J, Escobar F et al.. “Cytoplasmic membrane vesicles from Clostridioides difficile R20291 are remodeled by osmotic stress.” Frontiers in microbiology (2026). PMID: 42388301 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [112]
Fu M, Hu L, Han K et al.. “The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2025). PMID: 40122092 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Complications - [113]
Kelly CR, Allegretti JR. “Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051967 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control - [114]
Slimings C, Riley TV. “Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.” The Journal of antimicrobial chemotherapy (2021). PMID: 33787887 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [115]
Carlson TJ, Gonzales-Luna AJ. “Utilizing antibiotics to prevent Clostridioides difficile infection: does exposure to a risk factor decrease risk? A systematic review.” The Journal of antimicrobial chemotherapy (2020). PMID: 32696044 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Prognosis and Natural History, Prevention and Infection Control - [116]
Dulhunty JM, Brett SJ, De Waele JJ et al.. “Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.” JAMA (2024). PMID: 38864155 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [117]
Arabi YM, Alsaawi A, Alzahrani M et al.. “Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial.” JAMA (2025). PMID: 39658862 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [118]
Sauvat L, Verhoeven PO, Gagnaire J et al.. “Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.” Clinical microbiology reviews (2024). PMID: 39120140 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [119]
Gargis AS, Karlsson M, Paulick AL et al.. “Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36208202 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [120]
Perry DA, Shirley D, Micic D et al.. “External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34459885 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications, Prognosis and Natural History - [121]
Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History - [122]
Raponi M, Mancini R, Martinelli S et al.. “Infection prevention, control and antimicrobial stewardship measures in intensive in-patient rehabilitation setting: a systematic review.” Antimicrobial resistance and infection control (2026). PMID: 42192548 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [123]
Oltolini C, Piekarska A, Signori A et al.. “Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).” Blood reviews (2026). PMID: 42106226 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [124]
Wei Q, Cai Y, Lu G et al.. “Prediction models for recurrence and mortality in patients with clostridioides difficile infection: a systematic review and meta-analysis.” The Journal of hospital infection (2026). PMID: 42081949 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [125]
Landivar MC, Hartmann Rost I, Carvalho Kilson A et al.. “Efficacy of fluoroquinolone prophylaxis during induction phase in children with acute lymphoblastic leukemia: a systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 42065773 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations - [126]
Zhao Y, He X, Hu Y et al.. “Impact of the COVID-19 pandemic on the incidence of Clostridioides difficile infection based on hospital surveillance data: a systematic review and meta-analysis.” Antimicrobial resistance and infection control (2026). PMID: 41933426 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Prevention and Infection Control - [127]
Wei Q, Lu G, Diao H et al.. “The Incidence and Risk Factors of Antibiotic-Associated Diarrhea in Critically Ill Patients: A Systematic Review and Meta-Analysis.” Journal of gastroenterology and hepatology (2026). PMID: 41804814 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [128]
Skjøt-Arkil H, Rune Nanthan K, Chen M et al.. “Carrier prevalence of Clostridioides difficile in emergency departments and the association of prior antibiotic consumption: a combined cross-sectional and nested case-control study.” The Journal of antimicrobial chemotherapy (2023). PMID: 37409612 ↗
L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [129]
Lopez-Alcalde J, Mateos-Mazón M, Oliveira Conterno L et al.. “Decontamination of environmental surfaces in hospitals to reduce hospital-acquired infections: a systematic review.” Infection prevention in practice (2026). PMID: 41883627 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [130]
Guh AY, Mu Y, Winston LG et al.. “Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.” The New England journal of medicine (2020). PMID: 32242357 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [131]
Magill SS, O'Leary E, Janelle SJ et al.. “Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.” The New England journal of medicine (2018). PMID: 30380384 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [132]
Chen YC, Kuo YC, Chen MC et al.. “Case-Control Study of Clostridium innocuum Infection, Taiwan.” Emerging infectious diseases (2022). PMID: 35195517 ↗
L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [133]
Okafor CM, Clogher P, Olson D et al.. “Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.” Emerging infectious diseases (2023). PMID: 37081745 ↗
L2REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [134]
Daniel F, Abdallah B, Chaitou AR et al.. “Association between postoperative Clostridioides difficile infection and outcomes following pancreatoduodenectomy for pancreatic cancer: a national cohort study.” Surgical endoscopy (2026). PMID: 42257924 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [135]
Rhodes NJ, Jozefczyk CC, Moore WJ et al.. “Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2021). PMID: 33875439 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [136]
Snydman DR, McDermott LA, Thorpe CM et al.. “A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021.” Antimicrobial agents and chemotherapy (2023). PMID: 37728368 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [137]
Zhang J, Chen L, Gomez-Simmonds A et al.. “Antibiotic-Specific Risk for Community-Acquired Clostridioides difficile Infection in the United States from 2008 to 2020.” Antimicrobial agents and chemotherapy (2022). PMID: 36377887 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [138]
Wieczorkiewicz JT, Skinner AM, Cheknis A et al.. “Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.” Antimicrobial agents and chemotherapy (2024). PMID: 38953622 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [139]
Arensman K, Shields M, Beganovic M et al.. “Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32839223 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [140]
Karp J, Edman-Wallér J, Toepfer M et al.. “Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals.” The Journal of antimicrobial chemotherapy (2019). PMID: 30358837 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [141]
Tydeman F, Craine N, Kavanagh K et al.. “Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales.” The Journal of antimicrobial chemotherapy (2021). PMID: 34151964 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [142]
Moreels N, Boven A, Gressani O et al.. “The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.” The Journal of antimicrobial chemotherapy (2024). PMID: 38267263 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [143]
Yamamoto S, Shiroshita A, Kataoka Y et al.. “Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.” Open forum infectious diseases (2025). PMID: 40134633 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [144]
Ilett EE, Helleberg M, Reekie J et al.. “Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.” Open forum infectious diseases (2019). PMID: 30949533 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [145]
Rao K, Garey KW. “From Chaos to Clarity? The Quest for Effective Probiotics in Antibiotic-Associated Diarrhea.” Open forum infectious diseases (2024). PMID: 39529940 ↗
L5OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control - [146]
Olsen MA, Keller MR, Stwalley D et al.. “Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37547851 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [147]
Li X, Xiao F, Wang X et al.. “Gut Microbial and Metabolic Features Associated With Clostridioides difficile Infection Recurrence in Children.” Open forum infectious diseases (2024). PMID: 39319090 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control - [148]
Sanchez E, Krantz EM, Escobar ZK et al.. “Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.” Open forum infectious diseases (2024). PMID: 39450393 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [149]
Tartof SY, Schmidt MA, Contreras R et al.. “Burden of Medically Attended Diarrhea and Outpatient Clostridioides difficile Infection Among Persons in 2 Large Integrated Healthcare Settings, 2016-2021.” Open forum infectious diseases (2024). PMID: 38250203 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [150]
Williams MJ, Atienza S, Franzen E et al.. “Evaluation of Primary Oral Vancomycin Prophylaxis Against Clostridioides difficile Infection During Autologous Stem Cell Transplantation.” Open forum infectious diseases (2024). PMID: 39498172 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Prevention and Infection Control - [151]
Johnson TM, Howard AH, Miller MA et al.. “Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients.” Open forum infectious diseases (2021). PMID: 34262988 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [152]
Moloney G, Eyre DW, Mac Aogáin M et al.. “Human and Porcine Transmission of Clostridioides difficile Ribotype 078, Europe.” Emerging infectious diseases (2021). PMID: 34423760 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [153]
Du T, Choi KB, Silva A et al.. “Characterization of Healthcare-Associated and Community-Associated Clostridioides difficile Infections among Adults, Canada, 2015-2019.” Emerging infectious diseases (2022). PMID: 35470794 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [154]
Guo CLT, Kwong TNY, Mak JWY et al.. “Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong.” Emerging infectious diseases (2021). PMID: 34812719 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [155]
Miller AC, Arakkal AT, Sewell DK et al.. “Risk for Asymptomatic Household Transmission of Clostridioides difficile Infection Associated with Recently Hospitalized Family Members.” Emerging infectious diseases (2022). PMID: 35447064 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [156]
Capone D, Bakare T, Barker T et al.. “Risk Factors for Enteric Pathogen Exposure among Children in Black Belt Region of Alabama, USA.” Emerging infectious diseases (2023). PMID: 37987604 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [157]
Ramirez JA, Angulo FJ, Carrico RM et al.. “Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019-20201.” Emerging infectious diseases (2023). PMID: 37080953 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [158]
Dunn AN, Radakovich N, Ancker JS et al.. “The Impact of Clinical Decision Support Alerts on Clostridioides difficile Testing: A Systematic Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32060501 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Complications - [159]
Doolan CP, Sahragard B, Leal J et al.. “Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36718646 ↗
L1RCTCited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History - [160]
Doolan CP, Louie T, Lata C et al.. “Latent Class Analysis for the Diagnosis of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33053174 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis and Workup - [161]
Rock C, Abosi O, Bleasdale S et al.. “Clinical Decision Support Systems to Reduce Unnecessary Clostridioides difficile Testing Across Multiple Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35100620 ↗
L2OTHERCited in: Clinical Presentation - [162]
Kelly CP, Chen X, Williams D et al.. “Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31211839 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [163]
Guh AY, Hatfield KM, Winston LG et al.. “Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30615074 ↗
L3OTHERCited in: Clinical Presentation, Special Hosts and Populations - [164]
Turner NA, Krishnan J, Nelson A et al.. “Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37279965 ↗
L2OTHERCited in: Clinical Presentation - [165]
Yan AP, Yi M, Patel P et al.. “Use of Electronic Health Records to Benchmark Clinical Practice Guideline-Consistent Care in Pediatric Oncology.” JCO clinical cancer informatics (2026). PMID: 41886707 ↗
L5GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Prevention and Infection Control, Special Hosts and Populations - [166]
Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications - [167]
McKay V, Malone S, Tetteh E et al.. “Facilitation as an effective strategy to reduce excessive antibiotic prophylaxis in Children's hospitals: A stepped-wedge cluster randomized controlled trial.” Implementation science : IS (2025). PMID: 41121325 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prevention and Infection Control, Special Hosts and Populations - [168]
Salvador BC, Gomes DL, Araujo AGS et al.. “Systematic review: Accuracy of diagnostic methods for Clostridioides difficile infection.” Anaerobe (2026). PMID: 41833705 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup - [169]
Wang C, Gao H, Zhu C et al.. “Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses.” BMJ evidence-based medicine (2026). PMID: 42303374 ↗
L1SR_OBSCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History, Prevention and Infection Control - [170]
Aràjol C, González Suárez B, Bonilla Moreno M et al.. “Clostridioides difficile infection: Position paper of the Catalan Society of Gastroenterology.” Gastroenterologia y hepatologia (2026). PMID: 41547475 ↗
L1GUIDELINECited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [171]
Kozák M, Majoros L, Panyiczki Z et al.. “Severe vitamin K deficiency-associated coagulopathy triggered by Clostridioides difficile infection and antibiotic-associated dysbiosis: A case report and literature review.” Infection (2026). PMID: 41563580 ↗
L4CASE_REPORTCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [172]
AlAwadhi HK, Hyesoo Chang N, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [173]
Guh AY, Li R, Korhonen L et al.. “Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences.” Open forum infectious diseases (2024). PMID: 38577028 ↗
L3OTHERCited in: Clinical Presentation - [174]
Harrison CJ, Hassan F, Lee B et al.. “Multiplex PCR Pathogen Detection in Acute Gastroenteritis Among Hospitalized US Children Compared With Healthy Controls During 2011-2016 in the Post-Rotavirus Vaccine Era.” Open forum infectious diseases (2021). PMID: 34988246 ↗
L3OTHERCited in: Clinical Presentation - [175]
Curry SR, Hecker MT, O'Hagan J et al.. “Natural History of Clostridioides difficile Colonization and Infection Following New Acquisition of Carriage in Healthcare Settings: A Prospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36905149 ↗
L2COHORTCited in: Diagnosis and Workup, Prognosis and Natural History - [176]
Darkoh C, Keita K, Odo C et al.. “Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35016207 ↗
L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [177]
Crotty M, Devall H, Cook N et al.. “Short Versus Long Antibiotic Duration in Streptococcus pneumoniae Bacteremia.” Open forum infectious diseases (2024). PMID: 39257675 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [178]
Wilcox MH, Rahav G, Dubberke ER et al.. “Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.” Open forum infectious diseases (2019). PMID: 31375837 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis and Workup - [179]
Barbero AM, Moriconi ND, Palma S et al.. “Epidemiology of Clostridioides difficile Infection in Argentina and Associated Risk Factors Evaluated Through a Meta-Analysis.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353652 ↗
L3SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [180]
Begum K, Bassères E, Miranda J et al.. “In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile.” Antimicrobial agents and chemotherapy (2020). PMID: 32513796 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [181]
Oka D, Yamaya N, Kuno T et al.. “In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.” Antimicrobial agents and chemotherapy (2021). PMID: 33495229 ↗
L5OTHERCited in: Diagnosis and Workup, Complications - [182]
Wickramage I, Spigaglia P, Sun X. “Mechanisms of antibiotic resistance of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2021). PMID: 34297842 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [183]
Skinner AM, Petrella LA, Cheknis A et al.. “Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials.” The Journal of antimicrobial chemotherapy (2023). PMID: 37279600 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [184]
Karczewski J, Brown CM, Maezato Y et al.. “Efficacy of a novel lantibiotic, CMB001, against MRSA.” The Journal of antimicrobial chemotherapy (2021). PMID: 33582800 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [185]
Youenou B, Martins Simoes P, Tristan A et al.. “Linezolid resistance: detection of the cfr(B) gene in French clinical MRSA strains.” The Journal of antimicrobial chemotherapy (2023). PMID: 36509546 ↗
L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [186]
Bassères E, Begum K, Lancaster C et al.. “In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.” The Journal of antimicrobial chemotherapy (2020). PMID: 32719870 ↗
L4OTHERCited in: Diagnosis and Workup - [187]
Oka D, Changkwanyeun R, Yamaguchi T et al.. “In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.” The Journal of antimicrobial chemotherapy (2022). PMID: 36101508 ↗
L4OTHERCited in: Diagnosis and Workup - [188]
Cheknis A, Devaris D, Chesnel L et al.. “Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.” The Journal of antimicrobial chemotherapy (2020). PMID: 32747931 ↗
L2OTHERCited in: Diagnosis and Workup - [189]
Vernon JJ, Wilcox MH, Freeman J. “Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness.” The Journal of antimicrobial chemotherapy (2019). PMID: 30590496 ↗
L5OTHERCited in: Diagnosis and Workup - [190]
Itogawa K, Narumoto O, Takeda K et al.. “Continuation of anti-tuberculosis therapy after Clostridioides difficile infection: a retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42296592 ↗
L2COHORTCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [191]
Jiang X, Wu L, Duan S et al.. “Long-Term Antibiotic-Driven Gut Microbiota Disruption Promotes Toxigenic Clostridioides difficile Proliferation: A Four-Year Retrospective Study of a Single ICU Patient.” Infection and drug resistance (2026). PMID: 41859067 ↗
L4COHORTCited in: Diagnosis and Workup - [192]
Lee MM, Reske KA, Hink T et al.. “Relationship Between Clostridioides difficile Stool Concentration, Nucleic Acid Amplification Test Results, and Environmental Contamination.” Open forum infectious diseases (2026). PMID: 41929670 ↗
L4OTHERCited in: Diagnosis and Workup - [193]
Yetsko A, Draper HM, Eid K et al.. “Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females.” Open forum infectious diseases (2023). PMID: 37779597 ↗
L2OTHERCited in: Diagnosis and Workup - [194]
Advani SD, Gao CA, Datta R et al.. “Knowledge and Practices of Physicians and Nurses Related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines.” Open forum infectious diseases (2019). PMID: 31375836 ↗
L4OTHERCited in: Diagnosis and Workup - [195]
Wo S, Dubrovskaya Y, Siegfried J et al.. “Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia.” Open forum infectious diseases (2020). PMID: 33511221 ↗
L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Complications - [196]
Smits WK, Harmanus C, Sanders IMJG et al.. “Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates.” Emerging infectious diseases (2022). PMID: 36286226 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [197]
Pipitò L, Anastasia A, D'Agati G et al.. “Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection in a critically ill patient with concomitant Clostridioides difficile colitis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42235915 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [198]
Maeda M, Mori N, Hiraide M et al.. “Evaluation of Antibiotic Use Metrics as Predictors of Clostridioides difficile Infection Onset: A Single-Center, Case-Control Study Assessing the Days of Therapy and the Days of Antibiotic Spectrum Coverage.” Biological & pharmaceutical bulletin (2026). PMID: 41765474 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [199]
Alzahrani N, Alfaouri H, Al Johani S. “Gastrointestinal pathogens detected by a multiplex PCR panel in a tertiary care center in Riyadh, Saudi Arabia (2023-2024).” Frontiers in public health (2026). PMID: 42317984 ↗
L4OTHERCited in: Diagnosis and Workup - [200]
Patterson WM, Fajnzylber J, Nero N et al.. “Diagnostic prediction models to identify patients at risk for healthcare-facility-onset Clostridioides difficile: A systematic review of methodology and reporting.” Infection control and hospital epidemiology (2023). PMID: 37665104 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [201]
Friedrichs A, Wenz R, Pape D et al.. “The effect of antibiotic therapy on clinical outcome in patients hospitalized with moderate COVID-19 disease: a prospective multi-center cohort study.” Infection (2025). PMID: 40569348 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [202]
Chen JH, Chiu CH, Chen CC et al.. “Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Clostridioides difficile Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study.” Biomedicines (2024). PMID: 39061970 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [203]
Chen W, Liu Y, Zhang Y et al.. “Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.” BMC gastroenterology (2024). PMID: 39448963 ↗
L1SR_OBSCited in: Severity Assessment and Risk Stratification - [204]
Wen BJ, Te LG, Liu XX et al.. “The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.” Frontiers in physiology (2022). PMID: 35991191 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [205]
Li J, Yang J, Ouyang Z et al.. “Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: A retrospective study.” Journal of global antimicrobial resistance (2025). PMID: 40287014 ↗
L4COHORTCited in: Severity Assessment and Risk Stratification - [206]
Le PH, Chen CL, Kuo CJ et al.. “Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study.” The Kaohsiung journal of medical sciences (2025). PMID: 40091757 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [207]
Tariq R, Sethi A, Arunachalam S et al.. “Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD).” The American journal of gastroenterology (2026). PMID: 41562450 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [208]
Rao K, Zhao Q, Bell J et al.. “An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37797310 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [209]
Llewelyn MJ, Budgell EP, Laskawiec-Szkonter M et al.. “Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.” The Lancet. Infectious diseases (2022). PMID: 36206793 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [210]
Young PJ, Bagshaw SM, Forbes AB et al.. “Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.” JAMA (2020). PMID: 31950977 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control - [211]
Johnstone J, Meade M, Lauzier F et al.. “Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.” JAMA (2021). PMID: 34546300 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History - [212]
Fischer M, Vaughn BP, Peery AF et al.. “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 42383946 ↗
L5GUIDELINECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prevention and Infection Control - [213]
Nhu NTQ, Young VB. “The Relationship Between the Microbiome and Antimicrobial Resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051965 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [214]
Alonso CD, Tillotson GS, Bidell MR et al.. “Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.” Open forum infectious diseases (2025). PMID: 40177588 ↗
L2TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Complications - [215]
Phillips EC, Warren CA, Ma JZ et al.. “Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.” Antimicrobial agents and chemotherapy (2022). PMID: 35647645 ↗
L2COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [216]
Ordás I, Caballol B, Giordano A et al.. “Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the diagnosis and management of acute severe ulcerative colitis.” Gastroenterologia y hepatologia (2026). PMID: 42248446 ↗
L5GUIDELINECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [217]
Gonzales-Luna AJ, Skinner AM, Alonso CD et al.. “Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.” The Lancet. Infectious diseases (2023). PMID: 37062301 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [218]
Naz F, Petri WA. “Host Immunity and Immunization Strategies for Clostridioides difficile Infection.” Clinical microbiology reviews (2023). PMID: 37162338 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [219]
Allegretti JR, Mullish BH, Kelly C et al.. “The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.” Lancet (London, England) (2019). PMID: 31379333 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [220]
Berkefeld A, Berger FK, Gärtner BC et al.. “Clostridioides (Clostridium) difficile Pacemaker Infection.” Open forum infectious diseases (2020). PMID: 33324719 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control - [221]
Phan JR, Do DM, Truong MC et al.. “An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.” Antimicrobial agents and chemotherapy (2021). PMID: 34780262 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [222]
Hu X, Dong R, Huang S et al.. “CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.” Antimicrobial agents and chemotherapy (2023). PMID: 37052498 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [223]
Bishop EJ, Tiruvoipati R. “Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.” The Journal of antimicrobial chemotherapy (2022). PMID: 36441203 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [224]
Bassetti M, Cascio A, De Rosa FG et al.. “Management of Clostridioides difficile infection: an Italian Delphi consensus.” The Journal of antimicrobial chemotherapy (2024). PMID: 39008427 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [225]
O'Sullivan CE. “Antimicrobial stewardship failure: time for a new model.” The Journal of antimicrobial chemotherapy (2020). PMID: 32068845 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [226]
Ronda M, Padullés A, Grau I et al.. “Impact of a prospective audit and feedback antimicrobial stewardship programme on carbapenem consumption: a quasi-experimental study (IPANEMA study).” The Journal of antimicrobial chemotherapy (2023). PMID: 37248767 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [227]
Sun Y, Veccia D, Song G et al.. “Acid-Suppressive Therapy Choice and Risk of Treatment Escalation in Inflammatory Bowel Disease: A Real-World Comparative Retrospective Study to Inform Personalized Treatment.” Journal of personalized medicine (2026). PMID: 42042559 ↗
L2COHORTCited in: Empiric Management, Acute Care and Source Control - [228]
Feuerstadt P, Harvey A, Yoho DS et al.. “Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 37256213 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History - [229]
Mehta N, Goodenough D, Gupta NK et al.. “Recurrent Clostridioides difficile Infection and Outcome of Fecal Microbiota Transplantation Use: A Population-Based Assessment.” Open forum infectious diseases (2024). PMID: 38975247 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [230]
Stewart AG, Chen SCA, Hamilton K et al.. “Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia.” Open forum infectious diseases (2023). PMID: 37274181 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [231]
de la Villa S, Herrero S, Muñoz P et al.. “Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection.” Open forum infectious diseases (2023). PMID: 36776780 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [232]
Hunt A, Danziger LH, Johnson S et al.. “Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection.” Open forum infectious diseases (2024). PMID: 38665169 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [233]
Tillotson G, Archbald-Pannone L, Johnson S et al.. “Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities.” Open forum infectious diseases (2022). PMID: 36686631 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control, Complications - [234]
Selvarajan T, Kannekanti L, Green A et al.. “Breaking the storm: canakinumab as salvage therapy for refractory macrophage activation syndrome in pediatric systemic lupus erythematosus-a case report.” Pediatric rheumatology online journal (2026). PMID: 42243916 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [235]
Mudrik-Zohar H, Ong SWX, Tong SYC et al.. “Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 42397386 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [236]
Kitagawa H, Aso S, Hirano Y et al.. “Effect of Broad-Spectrum Antibiotic Prophylaxis on Post-Pancreatoduodenectomy Infectious Complications: Nationwide Inpatient Database Study in Japan.” Annals of gastroenterological surgery (2026). PMID: 42395136 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [237]
Yousef A, Wang N, Yousef M et al.. “Evaluating the Risk of Clostridioides difficile Infection After Rifaximin Treatment for Small Intestinal Bacterial Overgrowth.” Journal of clinical medicine (2026). PMID: 42355617 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [238]
Berenson CS, Lashner B, Korman LY et al.. “Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37539715 ↗
L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [239]
Klompas M, McKenna C, Ochoa A et al.. “Ultra-Short-Course Antibiotics for Suspected Pneumonia With Preserved Oxygenation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35883250 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [240]
Ilges D, Ritchie DJ, Krekel T et al.. “Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34805436 ↗
L2COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [241]
McDonald EG, Butler-Laporte G, Brophy JM et al.. “Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41758514 ↗
L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [242]
Bryant JA, Vulić M, Walsh EA et al.. “The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.” Nature medicine (2026). PMID: 41491103 ↗
L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [243]
Chu T, Yuan X, Wang T et al.. “The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies.” PeerJ (2026). PMID: 41907457 ↗
L2SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [244]
Yee KL, Kleijn HJ, Kerbusch T et al.. “Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.” Antimicrobial agents and chemotherapy (2019). PMID: 30455246 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [245]
Greenfield A, Marsh K, Siegfried J et al.. “Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.” Open forum infectious diseases (2021). PMID: 34993258 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [246]
Britt RS, LaSalvia MT, Padival S et al.. “Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.” Open forum infectious diseases (2019). PMID: 32128338 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [247]
Alkhushaym N, Alabbad R, Alqarni YS et al.. “Assessment of rifaximin and rifampicin resistance across Clostridioides difficile ribotypes: a systematic review and meta-analysis.” Letters in applied microbiology (2026). PMID: 41604218 ↗
L2SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [248]
Psarrakis C, Tziolos NR, Matzarakis V et al.. “A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.” Cell reports. Medicine (2026). PMID: 41483804 ↗
L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [249]
Kaple CE, Cadnum JL, Redmond SN et al.. “A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool.” Journal of clinical microbiology (2026). PMID: 42283494 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [250]
Arias-Sánchez A, Casadiego-Payares S, Acosta-Parada C et al.. “Age-related clinical and therapeutic differences during a hospital outbreak of Clostridioides difficile infection in Colombia.” American journal of infection control (2026). PMID: 42217737 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [251]
Olesen RH, Larsen EB, Rubak T et al.. “Cost-Effectiveness of Hospital-at-Home and Fecal Microbiota Transplantation in Treating Older Patients With Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40243343 ↗
L2RCTCited in: History and Evolution of Treatment - [252]
Morgan DJ, Dubberke ER, Hink T et al.. “The Impact of Universal Glove and Gown Use on Clostridioides Difficile Acquisition: A Cluster-Randomized Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35776131 ↗
L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [253]
Rock C, Hsu YJ, Curless MS et al.. “Ultraviolet-C Light Evaluation as Adjunct Disinfection to Remove Multidrug-Resistant Organisms.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34636853 ↗
L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [254]
Cook D, Deane A, Lauzier F et al.. “Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.” The New England journal of medicine (2024). PMID: 38875111 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control - [255]
Vehreschild MJGT, Ducher A, Louie T et al.. “An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.” The Journal of antimicrobial chemotherapy (2022). PMID: 35016205 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [256]
Garey KW, Begum K, Lancaster C et al.. “A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.” The Journal of antimicrobial chemotherapy (2020). PMID: 32892222 ↗
L1RCTCited in: History and Evolution of Treatment - [257]
Reveles KR, Gonzales-Luna AJ, Golan Y et al.. “Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study.” Open forum infectious diseases (2024). PMID: 39006315 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [258]
Escudero-Sanchez R, Muriel García A, García Fernández S et al.. “Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.” The Journal of antimicrobial chemotherapy (2022). PMID: 35403189 ↗
L2COHORTCited in: History and Evolution of Treatment - [259]
Eriksen LL, Støy S, Mejlby Hansen M et al.. “Dynamics in Circulating Immune Cell Subsets After Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.” Clinical and translational gastroenterology (2026). PMID: 41738638 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [260]
Ayele H, Jo J, Begum K et al.. “A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk.” The Journal of infectious diseases (2025). PMID: 41081530 ↗
L1RCTCited in: History and Evolution of Treatment - [261]
Keating JA, McKinley L, Dolan K et al.. “Health care worker experiences with a universal gloving intervention to prevent Clostridioides difficile infection: A qualitative study.” American journal of infection control (2025). PMID: 41046913 ↗
L5RCTCited in: History and Evolution of Treatment, Prevention and Infection Control - [262]
Marreddy RKR, Nguyen N, Dureja C et al.. “Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent.” Antimicrobial agents and chemotherapy (2025). PMID: 41405459 ↗
L5OTHERCited in: History and Evolution of Treatment - [263]
Deshpande A, Wu X, Huo W et al.. “Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases.” Antimicrobial agents and chemotherapy (2020). PMID: 32457109 ↗
L5OTHERCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [264]
Karlowsky JA, Adam HJ, Baxter MR et al.. “Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.” The Journal of antimicrobial chemotherapy (2020). PMID: 32294172 ↗
L4OTHERCited in: History and Evolution of Treatment - [265]
Collins CD, Bookal RS, Malani AN et al.. “Antibiotic Use in Patients With β-Lactam Allergies and Pneumonia: Impact of an Antibiotic Side Chain-Based Cross-Reactivity Chart Combined With Enhanced Allergy Assessment.” Open forum infectious diseases (2021). PMID: 34988249 ↗
L2OTHERCited in: History and Evolution of Treatment - [266]
Straub TJ, Lombardo MJ, Bryant JA et al.. “Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37823484 ↗
L1RCTCited in: Antimicrobial Resistance and Stewardship - [267]
Aslan AT, Tanriverdi LH, Hernandez AV et al.. “Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Open forum infectious diseases (2025). PMID: 41018707 ↗
L1SR_MA_RCTCited in: Antimicrobial Resistance and Stewardship, Complications - [268]
Baker MA, Sands KE, Huang SS et al.. “The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34370014 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [269]
Ray MJ, Strnad LC, Tucker KJ et al.. “Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38743579 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [270]
Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗
L1TRIAL_NONRANDOMCited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [271]
Esberard M, Hallier M, Liu W et al.. “6S RNA-Dependent Susceptibility to RNA Polymerase Inhibitors.” Antimicrobial agents and chemotherapy (2022). PMID: 35389235 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [272]
Sandhu BK, Edwards AN, Anderson SE et al.. “Regulation and Anaerobic Function of the Clostridioides difficile β-Lactamase.” Antimicrobial agents and chemotherapy (2019). PMID: 31611350 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [273]
Kolte B, Nübel U. “Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.” The Journal of antimicrobial chemotherapy (2024). PMID: 38598696 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [274]
Raybardhan S, Langford B, Forrest R et al.. “Institutional spillover effects of antimicrobial use on antimicrobial resistance and Clostridioides difficile: a systematic review.” Antimicrobial stewardship & healthcare epidemiology : ASHE (2026). PMID: 42064230 ↗
L2SR_OBSCited in: Antimicrobial Resistance and Stewardship - [275]
Boyanova L, Boyanova LY, Medeiros J et al.. “Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353704 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [276]
Ryazanov V, Vershinina I, Inchagova K et al.. “Fecal microbiota and microbial community transplantation: a review of current research.” Frontiers in microbiology (2026). PMID: 42326403 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [277]
Samuelsen Ø, López-Causapé C, Aarestrup FM et al.. “The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the European Committee on Antimicrobial Susceptibility Testing Subcommittee.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42142806 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [278]
Abdessamad H, Abdallah D, Attieh R et al.. “Revisiting fluoroquinolone prophylaxis in haematological malignancies and hematopoietic cell transplantation: A decade of evidence and gaps in understanding the impact of gut colonization with fluoroquinolone-resistant Enterobacterales.” International journal of antimicrobial agents (2026). PMID: 42055352 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [279]
Eubank TA, Dureja C, Gonzales-Luna AJ et al.. “Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Specific Ribotypes.” Open forum infectious diseases (2024). PMID: 39512425 ↗
L3OTHERCited in: Antimicrobial Resistance and Stewardship - [280]
Endres BT, Begum K, Sun H et al.. “Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains.” Open forum infectious diseases (2019). PMID: 30793006 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [281]
Eudy JL, Pallotta AM, Neuner EA et al.. “Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort.” Open forum infectious diseases (2020). PMID: 33269298 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [282]
Hourigan SK, Ahn M, Gibson KM et al.. “Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden.” Open forum infectious diseases (2019). PMID: 31660343 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [283]
Tsalik EL, Prasad NK, Fleisher LA. “Advancing Antimicrobial Stewardship With Diagnostic Excellence: The Role of Bayesian Reasoning.” Open forum infectious diseases (2026). PMID: 42052289 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [284]
Gonzales-Luna AJ, Carlson TJ, Garey KW. “Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 38051970 ↗
L5REVIEW_NARRATIVECited in: Complications - [285]
Bej TA, Wilson BM, Akpoji UC et al.. “Feasibility of a Low-Intensity Intervention to Influence Antibiotic Prescribing Rates Use in Outpatient Settings: A Cluster Randomized Controlled Clinical Trial.” Open forum infectious diseases (2024). PMID: 39758744 ↗
L1TRIAL_NONRANDOMCited in: Complications - [286]
Baral B, Parajuli M, Pinilla J et al.. “Safety and efficacy of oral microbiome therapy for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.” Scandinavian journal of gastroenterology (2026). PMID: 41543263 ↗
L1SR_MA_RCTCited in: Complications - [287]
Omar MA, Katrib M, Shekhar R et al.. “Proton Pump Inhibitor Use for Gastroprotection and Stress Ulcer Prophylaxis Does Not Increase the Risk of Clostridioides difficile Infection or Pneumonia: A Systematic Review and Meta-Analysis of RCTs.” Journal of clinical medicine (2026). PMID: 41976918 ↗
L1SR_OBSCited in: Complications, Prevention and Infection Control - [288]
Nashtar MA, Garipoglu G, Traut I et al.. “From ward to intensive care unit: clinical drivers of adverse outcomes in Clostridioides difficile infection - A retrospective cohort study.” The Journal of hospital infection (2026). PMID: 41653983 ↗
L3COHORTCited in: Complications - [289]
Greco Kinney A, Kovacic Scherrer N, Sarkar S et al.. “β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.” The Journal of antimicrobial chemotherapy (2023). PMID: 37814829 ↗
L2OTHERCited in: Complications - [290]
Renoncourt T, Dossoubadjiokila J, Mondet L et al.. “Evaluation of the tolerance of ceftriaxone by subcutaneous route in patients ≥75 years old in geriatric departments: a prospective observational study.” The Journal of antimicrobial chemotherapy (2023). PMID: 37051882 ↗
L4OTHERCited in: Complications - [291]
Tucker EC, Angelica B, Mathias RM et al.. “Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia.” Open forum infectious diseases (2025). PMID: 40160347 ↗
L4OTHERCited in: Complications - [292]
Madden GR, Enfield KB, Sifri CD. “Patient Outcomes With Prevented vs Negative Clostridioides difficile Tests Using a Computerized Clinical Decision Support Tool.” Open forum infectious diseases (2020). PMID: 32328506 ↗
L3OTHERCited in: Complications - [293]
Turner NA, Warren BG, Gergen-Teague MF et al.. “Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34017999 ↗
L1RCTCited in: Prognosis and Natural History - [294]
Sahrmann JM, Olsen MA, Stwalley D et al.. “Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36285546 ↗
L3OTHERCited in: Prognosis and Natural History - [295]
Yu H, Alfred T, Nguyen JL et al.. “Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35686435 ↗
L3OTHERCited in: Prognosis and Natural History - [296]
Pruna ED, Davidescu L, Sorop-Florea M et al.. “Multimodal Hand Hygiene Interventions and Clinical Healthcare-Associated Infection Outcomes in Acute Care Hospitals: A Systematic Review of Quasi-Experimental Studies.” Journal of clinical medicine (2026). PMID: 42194842 ↗
L2SR_OBSCited in: Prognosis and Natural History - [297]
Chen W, Pan X, Ji J et al.. “Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis.” Frontiers in nutrition (2026). PMID: 41878577 ↗
L1SR_OBSCited in: Prognosis and Natural History - [298]
De Wolfe TJ, Kates AE, Barko L et al.. “Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies.” Antimicrobial agents and chemotherapy (2019). PMID: 30988143 ↗
L5OTHERCited in: Prognosis and Natural History - [299]
Shen WJ, Deshpande A, Hevener KE et al.. “Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates.” The Journal of antimicrobial chemotherapy (2020). PMID: 31873741 ↗
L5OTHERCited in: Prognosis and Natural History - [300]
West RM, Smith CJ, Pavitt SH et al.. “'Warning: allergic to penicillin': association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes.” The Journal of antimicrobial chemotherapy (2019). PMID: 31225607 ↗
L3OTHERCited in: Prognosis and Natural History - [301]
Pereira JA, McGeer A, Tomovici A et al.. “The Clinical Burden of Clostridioides difficile in Ontario, Canada.” Open forum infectious diseases (2019). PMID: 32025524 ↗
L2OTHERCited in: Prognosis and Natural History - [302]
Dorazio J, Chiappelli AL, Shields RK et al.. “Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection.” Open forum infectious diseases (2023). PMID: 37351452 ↗
L2OTHERCited in: Prognosis and Natural History - [303]
Alsoubani M, Chow JK, Rodday AM et al.. “Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study.” Open forum infectious diseases (2023). PMID: 38204563 ↗
L2OTHERCited in: Prognosis and Natural History - [304]
Johnson SW, Brown SV, Priest DH. “Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31560051 ↗
L1RCTCited in: Prevention and Infection Control - [305]
Poirier D, Gervais P, Fuchs M et al.. “Predictors of Clostridioides difficile Infection Among Asymptomatic, Colonized Patients: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31290544 ↗
L2COHORTCited in: Prevention and Infection Control - [306]
Heil EL, Harris AD, Brown C et al.. “A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33972996 ↗
L2OTHERCited in: Prevention and Infection Control - [307]
Butler AM, Nickel KB, Olsen MA et al.. “Comparative Safety of Different Antibiotic Regimens for the Treatment of Outpatient Community-Acquired Pneumonia Among Otherwise Healthy Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 39442057 ↗
L2OTHERCited in: Prevention and Infection Control - [308]
Pakyz AL, Orndahl CM, Johns A et al.. “Impact of the Centers for Medicare and Medicaid Services Sepsis Core Measure on Antibiotic Use.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32827032 ↗
L2OTHERCited in: Prevention and Infection Control - [309]
Wombwell E, Patterson ME, Bransteitter B et al.. “The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32575126 ↗
L2OTHERCited in: Prevention and Infection Control - [310]
Jones KM, Greene MT, Meddings J et al.. “Impact of a Collaboration-Focused Intervention to Prevent Healthcare-Associated Infections Before and During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40298392 ↗
L2OTHERCited in: Prevention and Infection Control - [311]
Brothers AW, Pak DJ, Poole NM et al.. “Individualized Antibiotic Plans as a Quality Improvement Initiative to Reduce Carbapenem Use for Hematopoietic Cell Transplant Patients at a Freestanding Pediatric Hospital.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37647637 ↗
L4OTHERCited in: Prevention and Infection Control, Special Hosts and Populations - [312]
DeJohn I, Liu C, Brammer C et al.. “Secondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study.” Open forum infectious diseases (2026). PMID: 42403911 ↗
L2COHORTCited in: Prevention and Infection Control - [313]
Keating JA, Xu T, Graham MB et al.. “Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.” JAMA network open (2025). PMID: 40601321 ↗
L1RCTCited in: Prevention and Infection Control - [314]
Tetteh EK, Obeng H, Atkinson A et al.. “Dissemination of a facilitation strategy to de-implement unnecessary post-operative antibiotics at children's hospitals: The Optimizing Perioperative Antibiotic in Children (OPerAtiC) trial 2.0.” Implementation science : IS (2025). PMID: 41214788 ↗
L5TRIAL_NONRANDOMCited in: Prevention and Infection Control, Special Hosts and Populations - [315]
Hirsch W, Fischer M, Khoruts A et al.. “Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study.” Open forum infectious diseases (2025). PMID: 40103733 ↗
L2OTHERCited in: Prevention and Infection Control - [316]
Prosty C, Bortolussi-Courval É, Lee J et al.. “Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians.” Open forum infectious diseases (2025). PMID: 40395460 ↗
L5OTHERCited in: Prevention and Infection Control - [317]
Wolf J, Kalocsai K, Fortuny C et al.. “Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773143 ↗
L1RCTCited in: Special Hosts and Populations - [318]
Barbar R, Brazelton JN, Carroll KC et al.. “Molecular Epidemiology and Genetic Relatedness of Clostridioides difficile Isolates in Pediatric Oncology and Transplant Patients Using Whole Genome Sequencing.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35675378 ↗
L2OTHERCited in: Special Hosts and Populations - [319]
Cherny KE, Muscat EB, Balaji A et al.. “Association Between Clostridium innocuum and Antibiotic-Associated Diarrhea in Adults and Children: A Cross-sectional Study and Comparative Genomics Analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 35724319 ↗
L4OTHERCited in: Special Hosts and Populations - [320]
Nussbaum EZ, Koo S, Kotton CN. “Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38195100 ↗
L2OTHERCited in: Special Hosts and Populations - [321]
Lee JD, Heintz BH, Mosher HJ et al.. “Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33382398 ↗
L2OTHERCited in: Special Hosts and Populations - [322]
Rogers WS, Westblade LF, Soave R et al.. “Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31687767 ↗
L4OTHERCited in: Special Hosts and Populations - [323]
Coritsidis GN, Yaphe S, Rahkman I et al.. “Outpatient Antibiotic Prescribing Patterns for Adult End-Stage Renal Disease Patients in New York State.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33277995 ↗
L3OTHERCited in: Special Hosts and Populations - [324]
O'Leary EN, Edwards JR, Srinivasan A et al.. “National Healthcare Safety Network Standardized Antimicrobial Administration Ratios (SAARs): A Progress Report and Risk Modeling Update Using 2017 Data.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32215655 ↗
L4OTHERCited in: Special Hosts and Populations - [325]
Longhitano A, Roder C, Blackmore T et al.. “Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand.” Internal medicine journal (2025). PMID: 40035163 ↗
L1GUIDELINECited in: Special Hosts and Populations - [326]
Berry P, Tariq R, Pardi DS et al.. “Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40759389 ↗
L4SR_OBSCited in: Special Hosts and Populations - [327]
Dell'Acqua R, Parrinello MH, Clerici D et al.. “Antibacterial prophylaxis and antimicrobial stewardship in the era of innovative therapies for haematological malignancies: transplantation, cellular therapies and new drugs.” JAC-antimicrobial resistance (2026). PMID: 41959696 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [328]
Wang R, Li X, Zhang T. “Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41723281 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [329]
Kinsella P, Thursky K, Slavin MA et al.. “From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts.” Expert review of anti-infective therapy (2025). PMID: 40785091 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [330]
Kociolek LK, Sandora TJ, Mehrotra P. “Clostridioides difficile in Children.” Infectious disease clinics of North America (2025). PMID: 40781053 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations